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Introduction
Lipids, one of the most common factors, which determine the
cardiac  health,  make  a  critical  part  in  the  research  areas  of
cardiology. This does not mean that lipids are foes of human beings.
Lipids, which include a wide variety of organic molecular chains, are
inevitable for normal functioning of the body including the brain, joint
mobilization and even energy production.1 Different types of lipids do
different things.
Lipids are very essential for absorption of fat-soluble vitamins.
They  coat  cell  membranes  and allow normal  cell  development  and
functioning. Lipids are a form of stored energy, as the human body is
more prone to fat storage, and supplies energy in emergencies. They
act as inter-cellular messengers inducing enzyme and protein kinases
production.2  Hormone  production  in  the  body  is  normal  until  the
lipids function normal.
If we have a look at the entire categorization of the lipids it will
become  clear  that  the  fact,  body  requires  lipids  in  enormous
proportion when compared to other nutrients for healthy functioning
of the body, is true.
Whenever there comes a swing of serum levels of lipids from the
normal,  then  the  body’s  normal  functioning  is  disturbed  and  the
health of the person get to be concerned. Persistent abnormal serum
levels of lipids lead to coronary artery diseases, obesity and lot more.
The serum lipid levels oscillate from the normal due to many factors
including fatty diet  and poor utilization of  lipids by the body.  This
patho-physiological condition is said ‘Dyslipidaemia’.
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Dyslipidaemia
Dyslipidaemia is a broad term that refers to a number of lipid
disorders that include increased as well as decreased levels of serum
lipid. It is widespread and imposes substantial costs on the healthcare
system. Research over the past 4 decades has consistently shown the
burden  of  dyslipidaemia  to  be  very  high  in  terms  of  morbidity,
mortality and medical costs.3
                          
Dyslipidaemia is  an important  major  risk  factor  for  coronary
heart  disease(CHD).The  world  health  organization  estimates  that
dyslipidaemia  is  associated  with  more  than  half  of  global  cases  of
ischaemic  heart  disease  and more  than 4  million deaths  per  year.
Over 7.2 million people die from coronary heart diseases worldwide,
more than from cancer or infectious causes.4
 
Epidemiological evidences state that every 1 % increase in LDL
leads to 1% increase in risk for CHD, also, every 1 % increase in HDL
leads to 2-3 % reduction of risk for CHD.5 80 % lipid disorders are
related to diet and lifestyle, although familial disorders are important
as well.
The  basic  categories  of  dyslipidaemias  include  elevated  low-
density lipoprotein (LDL), low high-density lipoprotein (HDL), excess
lipoprotein (a), hypertriglyceridaemia, atherogenic dyslipidaemia and
mixed  lipid  disorders.  Most  patients  with  CHD  have  mixed
dyslipidaemia  (e.g.,  elevated  LDL  and  low  HDL),  which  is  also
commonly seen in patients with diabetes mellitus (DM). A complete
overview of the classification of dyslipidaemias gives a clear cut image
of the different types of lipid disorders.
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Classification of Dyslipidaemia
Dyslipidaemia is usually classified on the basis of Phenotype or
Etiology Phenotype implies the presentation of dyslipidaemia in the
body including the specific type of lipid whose level has increased or
decreased. Etiology implies the reason for dyslipidaemia, whether, it is
genetic or secondary to other pathophysiological conditions. Basically,
dyslipidaemia includes abnormal levels of both lipids and, of course,
lipoproteins.
The  Fredrickson  classification6 is  a  perfect  example  of  the
phenotypic  classification,  although it  is  not  used now. Fredrickson
gives five phenotypes of dyslipidaemia. Table 1 represents that.
Table 1. Fredrickson Phenotypes
Phenotype Elevated Lipoproteins Elevated Lipids
I Chylomicrons TG
II a LDL Cholesterol
II b LDL and VLDL TG and Cholesterol
III
VLDL, IDL and
Chylomicron Remnants
TG and Cholesterol
IV VLDL TG
V
VLDL and
Chylomicrons
TG and Cholesterol
LDL: Low Density Lipoproteins; VLDL: Very Low Density Lipoproteins;
TG: Triglycerides; IDL: Intermediate Density Lipoproteins
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Even though, the phenotypic classification is simple and clear, a
much more informative classification which involves the primary and
the secondary reasons of dyslipidaemia becomes necessary. Table 2
gives a clear picture of the Etiologic classification7 of dyslipidaemia.
Table 2.Classification of Dyslipidaemia
Name
Lipid(s) &
Lipoprotein(s)
In Excess
Possible Cause(s) For
Elevated Levels
Polygenic
Hypercholesterolaemia
LDL,Cholesterol
Nutritional, Genetic(less
active LDL receptors)
Familial
Hypercholesterolaemia
LDL,Cholesterol
Genetic(defective gene for
the LDL receptors)
Diet-induced
Hypertriglyceridaemia
VLDL & TG
Excess intake of calories,
alcohol
Primary
Hpertriglyceridaemia
VLDL, TG &
LDL
Diet(often associated with
other medical problems like
obesity, diabetes)
Secondary
Hypertriglyceridaemia
VLDL & TG
Secondary to other medical
problems like
obesity,diabetes,nephritic
syndrome
Familial Combined
Hyperlipidaemia
VLDL, TG &
LDL
Genetic(overproduction of
apolipoprotein B-100)
Lipoprotein Lipase
Deficiency
Chylomicrons,
TG & VLDL
Genetic(Lipoprotein Lipase
enzyme deficiency)
LDL: Low Density Lipoproteins; VLDL: Very Low Density Lipoproteins;
TG: Triglycerides; HDL: High Density Lipoproteins
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In short,  the etiology of dyslipidaemia can be explained such
that primary dyslipidaemia are due to genetic make-up and secondary
dyslipidaemia  are  due  to  sedentary  life-style  and  other  underlying
pathophysiological conditions.
                      
Primary dyslipidaemia are most seen in children than in adults.
They are the consequences of gene mutations.8
Secondary  causes  contribute  to  dyslipidaemia  in  most  of  the
adults. It’s just primarily because of sedentary life-style. Consumption
of diet containing saturated fats, cholesterol and trans fats results in
increased  levels  of  lipids  in  the  blood.  Apart  from  diet,  medical
problems  like  diabetes,  chronic  kidney  disease,  hypothyroidism,
primary biliary cirrhosis, other cholestatic liver diseases and alcohol
overuse  also  contribute  to  dyslipidaemia.  Usage  of  drugs  such  as
thiazides,  β-blockers,  retinoids,  highly  active  anti-retroviral  agents,
oestrogen  and  progestins,  and  glucocorticoids  infact  cause
dyslipidaemia.9
The  classifications  alone  don’t  give  a  perfect  idea  about  the
lipids  and  the  lipoproteins  involved  in  the  human  physiology,  for
clinically managing dyslipidaemia. A closer view in to the Cholesterol
Homeostasis  gives  a  better  picture  of  the  lipid  transportation  and
utilization systems.
Cholesterol Homeostasis10
 Cholesterol is the lipid that primarily serves as the precursor to
steroid hormones and bile acids, and as the main component of cell
membranes. Cholesterol required for normal functioning of the body is
manufactured in the body and also ingested from exogenous dietary
sources. Cholesterol levels in the blood reflect approximately 40% to
60% endogenous cholesterol,  with the balance coming from dietary
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sources. Triglycerides, which are composed of fatty acids esterified to
glycerol and used as energy substrates, are supplied by fats in the diet
and through the conversion of carbohydrates by the liver.
Cholesterol,  triglycerides,  and  other  lipids  in  the  body  are
transported  as  spherical  particles,  through the  bloodstream,  called
lipoproteins. 
Lipoproteins  can  be  divided  in  to  five  major  categories
depending on their composition. Table 3 depicts that.
Table 3.Characteristics of the Major Classes of
Lipoproteins
Lipoproteins Composition Origin
Chylomicrons
Exogenous/Dietary
triglycerides
Gut
Very-low-density-
lipoproteins(VLDL)
Triglycerides Liver
Intermediate-
density
lipoproteins(IDL)
Cholesterol esters &
Triglycerides
VLDL/HDL
Catabolism
Low-density
lipoproteins(LDL)
Cholesterol VLDL Catabolism
High-density
lipoproteins(HDL)
Cholesterol Liver & Gut
The classes from largest and least dense to smallest and most
dense  are  chylomicrons,  very-low-density  lipoprotein  (VLDL),
intermediate-density  lipoprotein (IDL),  low-density lipoprotein (LDL),
and high-density lipoprotein (HDL). The larger, more floating particles
primarily have a triglyceride-rich core, while the smaller, and denser
particles have a cholesterol ester core.LDL accounts for approximately
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60% to 70% of total serum cholesterol and is the primary atherogenic
class of  lipoproteins.HDL constitutes approximately 20% to 30% of
total serum cholesterol with VLDL comprising about 10% to 15%.
Two main sources supply cholesterol to the body. It is obtained
exogenously  from  the  systemic  circulation  and  endogenously  via
intracellular synthesis. The systemic circulatory system is responsible
for  the  synthesis,  transportation,  and  catabolism  of  chylomicron
particles and remnants.
The  lipids  which  are  digested  and  absorbed  in  the  proximal
small  bowel are then converted to chylomicrons by the cells in the
intestinal  endothelium.  Thus,  chylomicrons basically  contain lipids,
fatty acids, cholesterol, and apolipoproteins, obtained from diet. These
chylomicrons then enter the lymphatic system and get converted to
chylomicron remnants, which are smaller,and contain less fatty acids,
and apolipoproteins B-48 and E.  These  remnants are then cleared
from the circulation by the LDL-related receptor protein found in the
liver.
In addition to utilizing circulating lipoproteins from exogenous
sources, cells can also synthesize their own cholesterol through the
endogenous pathway. The intracellular cholesterol synthesis involves
a series of biochemical reactions starting with acetyl-CoA. The enzyme
HMG-CoA synthetase, catalyzes the conversion of acetyl-CoA to HMG-
CoA. The other one, HMG-CoA reductase, catalyzes the conversion of
hepatic HMG-CoA to mevalonic acid, which is used in a later step in
the biosynthesis of cholesterol.
Fatty  acids  and  cholesterol  produced  by  the  body  are  then
transported through the endogenous pathway with the help of three
major lipoproteins,VLDL, LDL, and HDL. Triglycerides are synthesized
in liver, especially in the presence of excess carbohydrates, and later
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drained into the bloodstream as VLDL. VLDLs contain approximately
five times more triglycerides than cholesterol.
Once  released into  the bloodstream,  triglyceride  molecules  in
the VLDL particles are hydrolysed and used for  energy production,
primarily  by  heart  and skeletal  muscle,  or  stored in  fat  cells.  The
VLDL particles, are then cleared via 
the  hepatic  remnant  receptor,  or  by  further release  of  triglycerides
resulting in the formation of IDL particles.
  
The  triglceride  content  of  IDL  is  nearly  the  same  as  VLDL.
Lipolysis  continues  leading  to  much  smaller,  cholesterol-rich  LDL
particles. IDL particles have a short life span. Their cholesterol and
triglyceride  contents  do  not  significantly  influence  cholesterol
measurements. Less than 5% of cholesterol circulates in IDL particles,
but in certain cases it is not. 50% of IDL particles are cleared from the
circulation by the LDL receptor while the remaining is converted to
LDL particles.
LDL is the primary atherogenic lipoprotein, and the smaller the
size of  the LDL particle,  the more it  is able to penetrate into sub-
endothelial  tissue,  where  it  contributes  to  the  development  of
atherosclerosis.  Excessive  circulating  LDL  cholesterol  will  lead  to
atherogenic plaque formation in the vascular endothelium, potentially
leading to coronary artery disease (CAD).
                         
Two types of physiologically important LDL particles have been
recently identified to be highly associated with CHD risk. The first,
lipoprotein  (a)  [Lp  (a)]  particle,  and  the  other  one  is  atherogenic
lipoprotein phenotype B. This subclass is found in approximately 30%
of the population and is associated with a high risk of CHD.
Another  physiologically  important  lipoprotein  involved  in  the
endogenous pathway is HDL. HDL particles are rich in cholesterol like
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LDL,but very small. HDL is involved in reverse cholesterol transport,
causing  an  antiatherogenic  effect.  Efficiently,  HDL may  prevent  or
remove cholesterol deposits within the arterial wall.
Other beneficial roles of HDL cholesterol are
1. Preventing LDL oxidation by acting as an antioxidant
2. Reducing  platelet  aggregability  by  increasing  prostacyclin
production
3. Stabilizing serum prostacyclin and promotes fibrinolysis
4. Competitively inhibiting the uptake of LDL by endothelial cells
5. Preventing LDL aggregation and uptake by macrophages
6. Decreasing cholesterol and foam cell formation
7. Inhibiting  platelet  activation  by  LDL  through  the
phosphatidylinositol cycle
An important marker for abnormal metabolism of chylomicrons
and  VLDL  particles  is,  as  triglycerides  increase,  HDL  decreases.
Cholesterol found in VLDL and IDL particles are transported to the
liver for elimination.
HDL,  LDL,  and  VLDL  are  involved  in  the  transport  of
triglycerides and cholesterol from the liver to the body where they may
be used by cells and from the body to the liver where they may be
eliminated. The cell will up-regulate its synthesis of the LDL receptor,
when  the  amount  of  cholesterol  is  insufficient  to  meet  the
requirements of any cell. This LDL receptor will migrate to an area on
the surface of the cell called the ‘coated pits’.
Once  in  the  coated  pits,  the  cell  recognizes  circulating
lipoproteins VLDL, IDL, and LDL particles. Since, both the VLDL and
IDL particles contain both B and E proteins they may have a higher
binding affinity for the LDL receptor than the LDL particles.
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Immediately after getting bound the lipoproteins are internalized
by the cell, and taken up by the liposomes, and then broken down to
get  used  by  the  cell.  The  same  process  continues  to  maintain
homeostasis.
Link between Lipids and CHD
Atherosclerosis  is  the  inflammatory  process  which  is
responsible  for  the  risk  of  CHD.  Lipids  are  known  to  have  an
important role in developing an atherosclerotic plaque.
With advancing age, as changes occur within the blood vessel
wall,  other "intruders" enter into the battle.11 These "intruders"  are
constituents of the atherosclerotic process, which has some aspects in
common with the aging process. However, unlike the aging process
within  blood  vessels,  atherosclerosis  includes  cholesterol
accumulation and recruitment of other blood cells to join the battle.
These cells are called ‘the inflammatory cells’.
Atherosclerosis is so common in older persons such that at least
one out of two persons over sixty five years of age has atherosclerosis.
It  was  previously  thought  that  it  was  part  of  the  "normal  aging
process". An alternate view is that atherosclerosis is a disease process
that takes advantage of the changes that occur within the artery with
aging.
The vascular aging process and the atherosclerotic process go
hand-in-hand,  and they influence each other.  The  more severe the
vascular  aging  process,  the  easier  it  is  for  atherosclerosis  to  take
power; the more severe your atherosclerosis, the bigger its impact on
the vascular aging.
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Thus, it appears that the atherosclerosis process and the aging
process  make  situations  together  to  enable  the  disease  called
atherosclerosis to be more visible and more severe in older persons.
The risk factors of atherosclerosis seem to be, 12
        1. Diabetes
        2. Alcohol over-use 
        3. Raised blood pressure readings
        4. Increased blood cholesterol levels 
        5. High-fat diet 
        6. Increasing age 
        7. Obesity
        8. Personal or family history of heart disease
        9. Smoking
 In recent years, it has become apparent that atherosclerosis is a
chronic  inflammatory  process  affecting  large-  and  medium-sized
arteries throughout the cardiovascular system. The rate of progression
is variable with the lesions occurring primarily at sites of low shear
stress or increased turbulence, i.e., at sites of bifurcation or curvature
of the vessels.
The  early  stages  of  atherosclerosis  are  also  similar  to  the
reactions noted in asthma and consist of infiltration of the affected
site  by  T  lymphocytes  and  monocytes,  which  then  transform  into
macrophages (foam cells), followed by proliferation of fibrous tissue.
Eventually  in  its  natural  progression,  calcification  of  the
atheromatous plaque occurs. Minimal calcification is present even in
the ‘‘soft plaque.’’
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Pathogenesis of Plaque Formation13
                       
The  herald  lesion  in  the  arteries  is  endothelial  dysfunction
triggered  by  exposure  of  the  endothelium  to  one  or  more  of  the
following agents.
      1. Oxidized LDL particles
      2. Free radicals
      3. Elevated plasma homocysteine - an inborn error of metabolism
      4. Local genetic alteration
      5. Chronic systemic infection - Herpes viruses, Chlamydia
 Pneumonia, Helicobacter pylori
                        
Initially the endothelium attempts to repair itself by attracting
T-lymphocytes, monocytes and platelets to the injured site. When the
reparative process fails, the endothelium becomes permeable and the
lymphocytes and monocytes migrate into the deep layer of the intima
where a series of reactions occur attracting LDL particles to the site.
These  particles  are  engulfed  by  monocytes,  which  are  then
transformed into macrophages (foam cells). Smooth muscle cells begin
migrating from the media, and the fatty streak is formed. This stage is
a reversible one.
As the attempt at endothelial repair progresses, a fibrous cap
consisting of smooth muscle and collagen is formed. At the same time,
the  macrophages  and  monocytes  involved  in  the  original  reaction
begin to die resulting in the formation of a necrotic core covered by the
fibrous cap.
The  lesions,  atheromatous  plaques,  continue  to  enlarge  as
leucocytes  and  lipid  fragments  enter  the  lesions  at  the  shoulders,
which are the most vulnerable sites on the plaque.
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While the atheroma is increasing in size, the wall of the artery
expands due to the presence of the elastic tissue in the media in an
ongoing remodelling process. At the same time, small  blood vessels
(vasa  vasorum)  develop  to  maintain  the  viability  of  the  plaque.
Eventually  the  arterial  wall  can no longer  expand,  and the  plaque
begins to bulge into the vessel lumen. As a result of the remodelling
process, the presence of the atheromatous plaque is not recognized by
angiography until the plaque occupies up to 45% of the vessel wall
and luminal blood flow is compromised.
When the process continues, there is thinning of the fibrous cap
accompanied by fissuring of the endothelial surface. The occurrence of
several fissures can contribute to overt plaque rupture although the
attempt  at  maintaining  a  balance  between  rupture  and  repair
continues.  When the rate  of  fissuring surpasses the rate  of  repair,
overt plaque rupture occurs usually at the shoulder of the plaque.
With the rupture of the plaque, its contents consisting of lipid
fragments and cellular debris are released into the vessel lumen. The
shearing force may also result in rupture of the small vessels in the
plaque. These are exposed to thrombogenic agents on the endothelial
surface resulting in thrombus formation. If the thrombus formed is
large enough, luminal  occlusion occurs resulting in a ‘‘hard event’’
(myocardial infarction or stroke).
The  process  described  outlines  the  genesis  of  soft  plaque
rupture,  which  accounts  for  more  than 50% of  sudden  cardiac  or
cerebrovascular events. Among individuals experiencing these events,
warning signs are rare, and outcomes are frequently catastrophic.
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Effects of Atherosclerosis
                           
Effects  develop  very  gradually.14Many  times,  people  with
atherosclerosis have no symptoms until an artery is 40% clogged with
plaque.  Symptoms differ  widely  depending upon which arteries are
affected.
Coronary Artery Disease15
                           
The heart has its own arteries, the coronary arteries, so that it
can pump oxygenated blood to itself. If an artery is so narrow, part of
the heart may not get enough blood during increased physical activity.
The consequence is chest pain that goes away with rest. This chest
pain is technically called ‘stable angina’.
It becomes unstable,  when there is more frequent chest pain
with less physical activity than before or chest pain even at rest.
In  the  worst  scenario,  the  plaque  ruptures  and  platelets
aggregate at the site, large enough to obstruct blood flow significantly.
Cardiac muscle downstream would be deprived of blood and soon it
dies.  This  is  what  we  say  Myocardial  Infarction.  Otherwise,  ‘heart
attack’. Scar tissue eventually develops at the site of infarction and
takes the place of muscle.
The  heart  becomes  weaker  overall,  paving  way  to  congestive
heart  failure  down  the  line.  Scarring  can  also  affect  the  heart's
electrical  system,  producing  one  of  many  possible  abnormal  heart
rhythms.
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Disease Cerebrovascular
Cerebrovascular  diseases,  where  the  arteries  that  supply  the
brain with blood are narrowed, can cause transient ischemic attack (a
sudden loss of brain function with complete recovery within 24 hours)
and stroke. Symptoms may include weakness or paralysis on one side
of the body, trouble speaking or understanding speech, loss of vision
in one eye, muscle weakness, sudden trouble walking, dizziness, loss
of balance or coordination, and sudden severe headache.
Abdominal Aortic Aneurysm16
                                
Plaques can form in the aorta, the large artery coming up the
heart and down through the chest and abdomen. Atherosclerosis in
the abdominal aorta weaken the artery wall so that pressure from the
blood can stretch a  wall  segment  like  a  balloon.  This  is  called  an
aneurysm. If it widens enough, there is a risk of rupture and bleeding
requiring surgical intervention.
Mesenteric Ischemia
                                 
The mesenteric arteries supply the intestines and they, too, can
be prone to decreased blood flow from atherosclerosis. The result is
either temporary abdominal pain with eating or longer lasting pain
when an artery is completely occluded and a segment of intestine dies.
While  this  is  rare,  the  consequences  can  be  serious  and  life-
threatening. With intestinal tissue death, bacteria that normally live in
the  intestines  can  make  its  way  into  the  bloodstream or  into  the
abdominal  cavity  if  the  intestine  perforates.  Intestinal  bleeding  is
another complication.
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Peripheral Artery Disease17
Peripheral  artery  disease  affects  the  arteries  that  supply  the
arms and legs with oxygen-rich blood. Symptoms may include pain,
aching,  cramps,  numbness  or  sense  of  fatigue  in  the  leg  muscles
(intermittent  claudication),"Bruits" (blowing sounds your doctor  can
hear with a stethoscope that indicate turbulence in blood flow),hair
loss, thickened nails, smooth and shiny skin surface, skin that is cold
to the touch, and gangrene.
Clinical Aspects of Dyslipidaemia18
Symptoms & Signs of Dyslipidaemia
                                  
Dyslipidaemia itself usually causes no symptoms but can lead
to symptomatic  vascular  disease,  including  coronary  artery disease
(CAD)  and  peripheral  arterial  disease.  High  levels  of  TGs  (> 1000
mg/dL [> 11.3 mmol/L]) can cause acute pancreatitis. High levels of
LDL can cause eyelid xanthelasmas;  arcus corneae;  and tendinous
xanthomas  at  the  achilles,  elbow,  and  knee  tendons  and  over
metacarpophalangeal joints.
Patients  with  the  homozygous  form  of  familial
hypercholesterolaemia  may have  the  above  findings  plus  planar  or
cutaneous xanthomas. Patients with severe elevations of TGs can have
eruptive xanthomas over  the trunk,  back,  elbows, buttocks,  knees,
hands, and feet. Patients with the rare dysbetalipoproteinaemia can
have palmar and tuberous xanthomas. 
Severe hypertriglyceridaemia (> 2000 mg/dL [> 22.6 mmol/L])
can  give  retinal  arteries  and  veins  a  creamy  white  appearance
(lipaemia retinalis). Extremely high lipid levels also give a lactescent
(milky)  appearance  to  blood  plasma.  Symptoms  can  include
paraesthesias, dypsnoea, and confusion.
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Dyslipidaemia is linked to many diseases like heart disorders,
high blood pressure,  and diabetes.  The  latest  research  shows that
dyslipidaemia  is  also  linked  to  erectile  dysfunction.  According  to
research,  20%  of  men  who  suffer  from  erectile  dysfunction  have
dyslipidaemia.
Diagnosis of Dyslipidaemia
Serum Lipid  Profile  (measured total  cholesterol,  TG,  and HDL-
cholesterol and calculated LDL-cholesterol and VLDL)
Dyslipidaemia  is  suspected  in  patients  with  characteristic
physical  findings  or  complications  of  dyslipidaemia  (e.g.,
atherosclerotic disease). Primary lipid disorders are suspected when
patients  have  physical  signs  of  dyslipidaemia,  onset  of  premature
atherosclerotic disease (at < 60 yr), a family history of atherosclerotic
disease,  or  serum  cholesterol  >  240  mg/dL  (>  6.2  mmol/L).
Dyslipidaemia  is  diagnosed  by  measuring  serum  lipids.  Routine
measurements (lipid profile) include total cholesterol (TC), TGs, HDL-
cholesterol, and LDL-cholesterol.
Lipid profile measurement
                                  
TC, TGs, and HDL-cholesterol are measured directly. TC and TG
values  reflect  cholesterol  and  TGs  in  all  circulating  lipoproteins,
including chylomicrons, VLDL, IDL, LDL, and HDL. TC values vary by
10% and  TGs  by  up  to  25% day-to-day  even  in  the  absence  of  a
disorder. TC and HDL-cholesterol can be measured in the nonfasting
state, but most patients should have all lipids measured while fasting
for maximum accuracy and consistency.
Testing  should  be  postponed  until  after  resolution  of  acute
illness,  because  TGs  increase  and  cholesterol  levels  decrease  in
inflammatory states. Lipid profiles can vary for about 30 days after an
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acute MI. However, results obtained within 24 h after MI are usually
reliable enough to guide initial lipid-lowering therapy.
LDL-cholesterol values are most often calculated as the amount
of cholesterol not contained in HDL and VLDL. VLDL is estimated by
TG ÷ 5, because the cholesterol  concentration in VLDL particles is
usually 1/5 of the total lipid in the particle. Thus, LDL-cholesterol = TC
− [HDL-cholesterol + (TGs ÷ 5)] (Friedewald formula). This calculation
is  valid only when TGs are < 400 mg/dL and patients are fasting,
because eating increases TGs.  The calculated LDL-cholesterol value
incorporates  measures of  all  non-HDL,  nonchylomicron cholesterol,
including that in IDL and Lp (a).
LDL  can  also  be  measured  directly  using  plasma
ultracentrifugation, which separates chylomicrons and VLDL fractions
from  HDL  and  LDL,  and  by  an  immunoassay  method.  Direct
measurement may be useful in some patients with elevated TGs, but
these direct measurements are not routinely necessary.
 
The role of apo B testing is under study because values reflect
all non-HDL cholesterol (in VLDL, VLDL remnants, IDL, and LDL) and
may be more predictive of CAD risk than LDL alone.
Other tests
                                       
Patients with premature atherosclerotic cardiovascular disease,
cardiovascular disease with normal or near-normal lipid levels, or high
LDL levels  refractory  to  drug  therapy should  probably  have  Lp (a)
levels  measured.  Lp  (a)  levels  may  also  be  directly  measured  in
patients  with  borderline  high  LDL-cholesterol  levels  to  determine
whether  drug  therapy  is  warranted.  C-reactive  protein  and
homocysteine  measurement  may  be  considered  in  the  same
populations.
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Secondary causes
                                 
Tests  for  secondary  causes  of  dyslipidaemia  including
measurements of  fasting  glucose,  liver  enzymes,  creatinine,  thyroid
stimulating hormone (TSH),  and urinary protein should be done in
most  patients  with  newly  diagnosed  dyslipidaemia  and  when  a
component of the lipid profile has inexplicably changed for the worse.
Screening
A fasting lipid profile (TC, TGs, HDL-cholesterol, and calculated
LDL-cholesterol) should be obtained in all adults ≥ 20 yr and should
be repeated every 5 yr. Lipid measurement should be accompanied by
assessment of other cardiovascular risk factors, defined as diabetes
mellitus, cigarette use, hypertension, family history of CAD in a male
1st-degree relative before age 55 or a female 1st-degree relative before
age 65.
A definite age after which patients no longer require screening
has not been established, but evidence supports screening of patients
into  their  80s,  especially  in  the  presence  of  atherosclerotic
cardiovascular disease.
Indications  for  screening  patients  <  20 yr  are  atherosclerotic
risk factors, such as diabetes, hypertension, cigarette smoking, and
obesity;  premature  CAD in  a  parent,  grandparent,  or  sibling;  or  a
cholesterol level > 240 mg/dL (> 6.2 mmol/L) or known dyslipidaemia
in a parent. If information on relatives is unavailable, as in the case of
adopted  children,  screening  is  at  the  discretion of  the  health  care
practitioner.
Patients with an extensive family history of heart disease should
also be screened by measuring Lp (a) levels.
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Treatment
                                
Treatment  is  indicated  for  all  patients  with  cardiovascular
disease  (secondary  prevention)  and  for  some  without  (primary
prevention).  The  goal  of  treating  hyperlipidaemia  is  to  prevent  or
reduce the risk and complications of  cardiovascular  disease.  Lipid-
lowering  therapy reduces  the  risk  of  CHD in  high-risk  individuals.
Clinical trials have shown reductions of about 30% in relative risk of
CHD events and 20% for relative risk of death.
The  National  Institutes  of  Health's  National  Cholesterol
Education  Program  (NCEP)  Adult  Treatment  Panel  III  (ATPIII)
guidelines (Table 4 and Table 5) are the most common reference for
deciding  which  adults  should  be  treated.  The  guidelines  focus
primarily on reducing elevated LDL-cholesterol levels and secondarily
on treating high TGs, low HDL, and metabolic syndrome.
An alternate treatment guide (the Sheffield table) uses TC: HDL
ratios  combined  with  presence  of  CAD  risk  factors  to  predict
cardiovascular  risk,  but  this  approach  probably  leads  to
undertreatment.
Treatment of children is controversial; dietary changes may be
difficult to implement, and no data suggest that lowering lipid levels in
childhood effectively prevents heart disease in adulthood. Moreover,
the safety and effectiveness of long-term lipid-lowering treatment are
questionable. Nevertheless, the American Academy of Pediatrics (AAP)
recommends  treatment  for  some  children  who  have  elevated  LDL-
cholesterol levels.
Treatment  options  depend  on  the  specific  lipid  abnormality,
although different lipid abnormalities often coexist. In some patients,
a single abnormality may require several therapies; in others, a single
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treatment  may  be  adequate  for  several  abnormalities.  Treatment
should  always  include  treatment  of  hypertension  and  diabetes,
smoking cessation, and in patients with a 10-yr risk of MI or death
from CAD of ≥ 10% with low-dose daily aspirin. In general, treatment
options for men and women are the same.
Table 4.National Cholesterol Education Program Adult Treatment
Panel III Approach to Dyslipidemias
1. Measure fasting lipoproteins (in mg/dL):
TC (mmol/L) 
        < 200 (<5.17)                  -                 Desirable
        200–239 (5.17–6.18)       -                 Borderline high
        ≥ 240 (≥ 6.20)                 -                  High
LDL-cholesterol 
        < 100 (<2.58)                 -                 Optimal
        100–129 (2.58–3.33)      -                  Near optimal/above optimal
        130–159 (3.36–4.11)      -                  Borderline high
        160–189 (4.13–4.88)      -                  High
        ≥ 190 (≥ 4.91)                -                  Very high          
HDL- Cholesterol 
        < 40 (< 1.03)                  -                   Low
        ≥ 60 (≥ 1.55)                  -                   High 
TG
        < 150 (< 1.695)              -                   Desirable
        150–199 (1.695–2.249)  -                  Borderline high
        200–499 (2.26–5.639)    -                  High
        ≥ 500 (≥ 5.65)                -                 Very high
2. Identify CAD or CAD equivalents.
1. Peripheral arterial disease
2. Abdominal aortic aneurysm
3. Symptomatic carotid artery disease
4. Diabetes mellitus
5. Additional risk factors that confer 10-yr risk of MI or CAD death >20% 
3. Identify major CAD risk factors.
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1. Cigarette smoking
2. Hypertension (BP ≥ 140/90 or on antihypertensive drug)
3. Low HDL (≤ 40 mg/dL [1.03 mmol/L])
4. 4.Family history of premature CAD (CAD in male 1st-degree relative <
55 or in female 1st-degree relative < 65)
5. Age (men ≥ 45, women ≥ 55)
CAD: Coronary Artery Disease; LDL: Low Density Lipoproteins; TG:
Triglycerides; HDL: High Density Lipoproteins; TC: Total Cholesterol
Table 5. NCEP Adult Treatment Panel III Guidelines for Treatment
of Hyperlipidemia
Risk Category
Begin
Lifestyle
Changes If
Consider Drug
Therapy If
LDL Goal
High: CAD or CAD
equivalents (10-yr
risk > 20%)
LDL ≥ 100
mg/dL (≥
2.58
mmol/L)
LDL ≥ 100 mg/dL
(≥ 2.58 mmol/L)
Drugs optional if
LDL < 100 mg/dL
[< 2.58 mmol/L])
< 100 mg/dL < 70
mg/dL optional
Moderate high : ≥
2 risk factors with
10-yr risk 10 to
20%
LDL ≥ 130
mg/dL (≥
3.36
mmol/L)
LDL ≥ 130 mg/dL
(≥ 3.36 mmol/L)
< 130 mg/dL
< 100 mg/dL
optional
Moderate : ≥ 2 risk
factors with 10-yr
risk < 10%
LDL ≥ 130 mg/dL
(≥ 3.36 mmol/L)
LDL ≥ 160
mg/dL (≥
4.13
mmol/L)
< 130 mg/dL < 100
mg/dL optional
Lower
Lower : 0–1 risk
factor
LDL ≥ 160
mg/dL (≥
4.13
mmol/L)
LDL ≥ 190 mg/dL
(≥ 4.91 mmol/L)
Drug optional if
LDL 160–189
mg/dL [4.13–4.88
mmol/L])
< 160 mg/dL
CAD: Coronary Artery Disease; LDL: Low Density Lipoproteins;
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Treatment for Elevated LDL-Cholesterol
                               
In adults, ATPIII guidelines recommend treatment for those with
any of the following:
1. Elevated LDL-cholesterol levels and a history of CAD
2. Conditions which confer a risk for future cardiac events similar
to  that  of  CAD  itself  (CAD  equivalents,  defined  as  diabetes
mellitus,  abdominal  aortic  aneurysm,  peripheral  arterial
disease, and symptomatic carotid artery disease)
3. ≥ 2 CAD risk factors
ATPIII  guidelines  recommend  that  these  patients  have  LDL-
cholesterol levels lowered to < 100 mg/dL, but accumulating evidence
suggests that this target may be too high and a target LDL-cholesterol
< 70 mg/dL is an option for patients at very high risk (e.g., patients
with known CAD and diabetes, other poorly controlled risk factors,
metabolic syndrome, or acute coronary syndrome). When drugs are
used,  a  dose  providing  at  least  a  30  to  40%  decrease  in  LDL-
cholesterol is desirable.
For  children,  the  AAP  recommends  dietary  treatment  for
children  with  LDL-cholesterol  > 110  mg/dL.  Drug  therapy  is
recommended for children > 8 yr and with either of the following:
1. Poor response to dietary therapy, LDL-cholesterol ≥ 190 mg/dL,
and no family history of premature cardiovascular disease
2. LDL-cholesterol ≥ 160 mg/dL and a family history of premature
cardiovascular  disease  or  ≥ 2  risk  factors  for  premature
cardiovascular disease
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Childhood  risk  factors  besides  family  history  and  diabetes
include cigarette  smoking,  hypertension,  low HDL-cholesterol  (< 35
mg/dL), obesity, and physical inactivity.
Treatment  options  to  lower  LDL-cholesterol  in all  age  groups
include  lifestyle  changes  (diet  and  exercise),  drugs,  dietary
supplements,  procedural  interventions,  and experimental  therapies.
Many  of  these  options  are  also  effective  for  treating  other  lipid
abnormalities.  Exercise lowers LDL-cholesterol in some people; it is
also  essential  to  maintain  ideal  body  weight.  Dietary  changes  and
exercise should be the initial approach whenever feasible.
Non-drug Therapy19
Diet can decrease both cholesterol and triglyceride levels.
1. Total fat intake should be 30% or less of total energy intake.
2. Saturated fats should be 10% or less of total energy intake.
3. Dietary cholesterol should be less than 300 mg/day.
4. Saturated  fats  should  be  replaced  by  monounsaturated  or
polyunsaturated fats.
5. Five portions of fruit and vegetables should be eaten per day.
6. Two  portions  of  fish  should  be  eaten  per  week,  including  a
portion of oily fish.
7. Advice pregnant women to limit their intake of oily fish to two
portions a week.
8. Do not routinely recommend omega-3 fatty acid supplements or
plant sterols and stanols for primary prevention.
Other appropriate measures include weight reduction, regular
physical  exercise,  and,  when  appropriate,  additional  measures  to
reduce  cardiovascular  risk  such  as  smoking  cessation,  alcohol
reduction and blood pressure and blood glucose control.
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Lifestyle changes can involve diet and exercise. Dietary changes
include decreasing intake of saturated fats and cholesterol; increasing
the  proportion  of  dietary  fibre,  and  complex  carbohydrates;  and
maintaining ideal body weight. Referral to a dietitian is often useful,
especially  for  older  people.  The  length  of  time  for  which  lifestyle
changes should be attempted before beginning lipid-lowering drugs is
controversial. In patients at average or low cardiovascular risk, 3 to 6
months is reasonable. Generally, 2 to 3 visits with a patient over 2 to
3 months are sufficient to assess motivation and adherence.
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Drug Therapy 
Drugs are the next step when lifestyle changes are not effective.
However, for patients with extremely elevated LDL-cholesterol (> 200
mg/dL [> 5.2 
mmol/L]) and those at high cardiovascular risk, drug therapy should
accompany diet and exercise from the start.
Table 6. Lipid Lowering Drugs
Drug
Primary
Mechanism
Of Action
Usual Daily
Dose
Side Effects
Statins(Atorvastatin,Simvastatin
Lovastatin, Rosuvastatin…)
↑LDL
receptors,
↑LDL and
VLDL
catabolism
Variable
GI,constipation,
flatulence,dyspeps-
ia,headache
Fibrates(Fenofibrate,Gemfibrozil
,
Bezafibrate…)
↑VLDL
catabolism
600 mg
twice a day
GI,myalgias,incre-
ased liver function
tests
Nicotinic acid (niacin)
↑LDL catabolism
2-3 grams
three times
a day
GI,flushing,
hepato-
toxicity,prur
itus
10 mg once a dayMyalgia,abdominal
discomfortBile acid sequestrants
(Colestipol, Choles-tyramine…)
↑LDL
metabolism
12-30 grams
in 2-4 divided
doses
Constipation, bloat-
ing,abdominal pain,
gas
Dietary supplements (Vitamin E,
omega-3 fatty
acids…)↓Cholesterol absorption
Cholesterol absorption
inhibitor(Ezetimibe)
↓Lipid
peroxidation
3-4 gram
daily
No serious side
effects
↑: Increases; ↓: Decreases; GI: Gastro-Intestinal; LDL: Low Density
Lipoprotein; VLDL: Very Low Density Lipoprotein;
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Statins are the drugs and possibly treatment of choice for LDL-
cholesterol  reduction;  they  demonstrably  reduce  cardiovascular
mortality. Statins inhibit hydroxymethylglutaryl CoA reductase (HMG
CoA  reductase  inhibitor),  a  key  enzyme  in  cholesterol  synthesis,
leading  to  up-regulation  of  LDL  receptors  and  increased  LDL
clearance.  They reduce LDL-cholesterol  by up to 60% and produce
small  increases in HDL and modest decreases in TGs. Statins also
appear  to  decrease  intra-arterial  inflammation,  systemic
inflammation,  or  both  by  stimulating  endothelial  nitric  oxide
production and may have other beneficial effects.
                       
Adverse effects are rare but include liver enzyme elevations and
myositis  or  rhabdomyolysis.  Muscle  toxicity  without  elevation  in
enzyme levels has also been reported. Older patients,  patients with
several disorders, and patients taking several drugs are susceptible to
ADRs.
In  some  patients,  changing  from  one  statin  to  another  or
lowering the dose relieves the problem. Muscle toxicity seems to be
most  common when some of  the  statins  are used with drugs that
inhibit cytochrome P3A4 (e.g., macrolide antibiotics, azole antifungals,
cyclosporine) and with fibrates, especially gemfibrozil. The preference
of drug should be based on patient characteristics,  LDL-cholesterol
level, and provider discretion.
Bile  acid  sequestrants act  by  blocking  intestinal  bile  acid
reabsorption, forcing up-regulation of hepatic LDL receptors to recruit
circulating  cholesterol  for  bile  synthesis.  Cardiovascular  mortality
goes down when they are taken. Bile acid sequestrants are usually
used with statins or with nicotinic acid to augment LDL-cholesterol
reduction and are the drugs of choice for children and women who are
or are planning to become pregnant.
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Bile acid sequestrants are safe, but may cause adverse effects
like  bloating,  nausea,  cramping,  and  constipation.  They  may  also
increase  TGs,  so  they  are  contraindicated  in  patients  with
hypertriglyceridaemia.  Cholestyramine  and  colestipol,  but  not
colesevelam,  interfere  with  absorption  of  other  drugs,  notably
thiazides,  β-blockers,  warfarin,  digoxin, and thyroxine,an effect that
can  be  decreased  by  administration  4  h  before  or  1  h  after  other
drugs.
Cholesterol  absorption  inhibitors,  such  as  ezetimibe,  inhibit
intestinal absorption of cholesterol and phytosterol. Ezetimibe usually
lowers LDL-cholesterol by 15 to 20% and causes small increases in
HDL  and  a  mild  decrease  in  TGs.  Ezetimibe  can  be  used  as
monotherapy in patients intolerant to statins or added to statins for
patients on maximum doses with persistent LDL-cholesterol elevation.
ADRs are very uncommon.
                           
Dietary supplements like fibre supplements and commercially
available  margarines  and  other  products  containing  plant  sterols
(sitosterol  and campesterol)  or  stanols  lower LDL-cholesterol  levels.
The latter reduce LDL-cholesterol by up to 10% without affecting HDL
or TGs by competitively displacing cholesterol from intestinal micelles.
Procedural  approaches are  used  in  patients  with  severe
hyperlipidaemia (LDL-cholesterol  > 300 mg/dL) that is refractory to
conventional  therapy,  such  as  occurs  with  familial
hypercholesterolaemia. Options include LDL aphaeresis (in which LDL
is removed by extracorporeal plasma exchange), ileal bypass (to block
reabsorption of  bile  acids),  liver  transplantation  (which transplants
LDL  receptors),  and  portocaval  shunting  (which  decreases  LDL
production  by  unknown  mechanisms).  LDL  aphaeresis  is  the
procedure  of  choice  in  most  instances  when  maximally  tolerated
therapy fails to lower LDL adequately. Aphaeresis is also the usual
Department of Pharmacy Practice, K.M. College of Pharmacy, Madurai Page 29
                                                                                                                         Introduction
therapy  in  patients  with  the  homozygous  form  of  familial
hypercholesterolaemia  who  have  limited  or  no  response  to  drug
therapy.
Future therapies to reduce LDL include peroxisome proliferator–
activated  receptor  agonists  that  have  thiazolidinedione-like  and
fibrate-like  properties,  LDL-receptor  activators,  LPL  activators,  and
recombinant  apo  E.  Cholesterol  vaccination  (to  induce  anti-LDL
antibodies and hasten LDL clearance from serum) and gene transfer
are  theoretically  interesting  therapies  that  are  under  study  but
currently unavailable.
Treatment for Elevated Triglycerides (TG)
Though it is unclear if elevated TG independently contribute to
cardiovascular  disease,  they are associated with multiple  metabolic
abnormalities that contribute to CAD (e.g. metabolic syndrome, DM).
It can be said that lowering elevated TGs is beneficial. No target goals
exist, but levels < 150 mg/dL (< 1.7 mmol/L) are generally considered
desirable. Treatment of elevated TGs in children does not include any
special precaution.
The  overall  treatment  strategy is  to  first  execute  lifestyle
changes,  including  exercise,  weight  loss,  and  avoidance  of
concentrated dietary sugar and alcohol. Intake of 2 to 4 servings/week
of marine fish high in ω-3 fatty acids may be effective, but the amount
of  ω-3 fatty acids is often lower than needed; supplements may be
helpful.  In  diabetic  patients,  glucose  levels  should  be  strictly
controlled. If  these measures are unsuccessful, lipid-lowering drugs
should be considered. Patients with very high TGs should be given
drug therapy immediately at diagnosis to more quickly reduce the risk
of acute pancreatitis.
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Fibrates reduce TGs by around 50%. They appear to decrease
hepatic VLDL synthesis. Also hike up HDL by up to 20%. Fibrates
may cause GI  adverse effects,  like dyspepsia,  abdominal  pain,  and
elevated  liver  enzymes.  Cholelithiasis  is  uncommon.  Fibrates  may
potentiate muscle toxicity when used with statins and potentiate the
effects of warfarin. 
Nicotinic acid (niacin) is the most effective drug for increasing
HDL. It  appears to both increase HDL production and inhibit  HDL
clearance; it also may mobilize cholesterol from macrophages. Niacin
also decreases TGs and, in doses of 1500 to 2000 mg/day, reduces
LDL-cholesterol.
Niacin produces flushing, pruritus, and nausea; premedication
with low-dose  aspirin  may prevent these adverse effects.  Extended-
release niacin cause flushing very less often. Most OTC slow-release
niacin are not recommended; but the exception is polygel controlled-
release niacin.
Niacin can cause liver enzyme elevations and occasionally liver
failure, insulin resistance, and hyperuricaemia and gout. It may also
increase  serum homocysteine  levels.  In patients with average LDL-
cholesterol and below-average HDL-cholesterol levels, niacin combined
with statin treatment may be effective  in preventing cardiovascular
disorders.
Statins can be given to patients with TGs < 500 mg/dL if LDL-
cholesterol elevations are also present; statins can reduce both LDL-
cholesterol and TGs through reduction of VLDL. Fibrates are the drug
of choice only if TGs are elevated.
Omega-3  fatty  acids in  high  doses  (1  to  6  g/day  of
eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) can be
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effective in reducing TGs. The omega-3 fatty acids EPA and DHA are
the active ingredients in marine fish oil or ω-3 capsules. Adverse effect
may be eructation and diarrhoea. These may be reduced by giving the
fish oil capsules with meals in divided doses. Omega-3 fatty acids can
be a useful addition to other therapies.
Treatment for Low HDL
Treatment to increase HDL-cholesterol levels may decrease risk
of  death,  but  data  are  limited.  ATPIII  guidelines  define  low  HDL-
cholesterol  as  < 40 mg/dL [< 1.04 mmol/L];  the guidelines do not
specify an HDL-cholesterol target level and recommend interventions
to raise HDL-cholesterol only after LDL-cholesterol targets have been
reached.  Treatments  for  LDL-cholesterol  and  TG  reduction  often
increase  HDL-cholesterol,  and  the  3  objectives  can  sometimes  be
achieved simultaneously. No guidelines specifically address treatment
of low HDL-cholesterol in children.
Treatment  includes  lifestyle  changes such  as  an  increase  in
exercise  weight  loss.  Alcohol  raises  HDL-cholesterol  but  is  not
routinely  recommended  as  a  therapy  because  of  its  many  other
adverse  effects.  Drugs  are  useful  when  lifestyle  changes  alone  are
insufficient.
Nicotinic acid may also be useful
 
Fibrates increase  HDL.  Infusion  of  recombinant  HDL  (e.g.,
apoprotein  A-1  Milano,  an  HDL  variant  in  which  a  cysteine  is
substituted  for  an  arginine  at  position  173  allowing  for  dimer
formation) appears promising as a treatment for atherosclerosis but
requires further study.
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Treatment for Elevated Lp (a)
The upper limit  of  normal  for Lp (a)  is  about 30 mg/dL (0.8
mmol/L), but values in African-Americans run higher. Few data exist
to  guide  the  treatment  of  elevated Lp (a)  or  to  establish treatment
efficacy.  Niacin is the only drug that directly decreases Lp (a); it can
lower Lp (a) by ≤ 20% at higher doses. The usual approach in patients
with elevated Lp (a) is to lower LDL-cholesterol aggressively.
Treatment for Secondary Causes
Treatment  of  diabetic  dyslipidaemia  should  always  involve
lifestyle changes, with statins to reduce LDL-cholesterol,  fibrates to
decrease TGs, or both drugs. Metformin lowers TGs, which may be a
reason to choose it  over other oral  antihyperglycaemic drugs when
treating diabetes. Some thiazolidinediones (TZDs) increase both HDL-
cholesterol and LDL-cholesterol (probably the less atherogenic large,
buoyant type of LDL). Some TZDs also decrease TGs.
These  antihyperglycaemic  drugs  should  not  be  chosen  over
lipid-lowering drugs to treat lipid abnormalities in diabetic patients
but may be useful adjuncts. Patients with very high TG levels and less
than optimally controlled diabetes may have better response to insulin
than to oral antihyperglycaemic drugs.
Treatment  of  dyslipidaemia  in  patients  with  hypothyroidism,
renal  disease,  liver  disease,  or  a  combination  of  these  disorders
involves  treating  the  underlying  disorders  primarily  and  lipid
abnormalities secondarily. Abnormal lipid levels in patients with low-
normal  thyroid  function  (high-normal  TSH  levels)  improve  with
hormone replacement. Reducing the dosage of or stopping drugs that
cause lipid abnormalities should be considered.
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Other Drug Categories
Anion-exchange Resins20
1. Cholestyramine  and  colestipol  act  by  binding  bile  acids,
preventing  their  reabsorption.  The  resultant  increased  LDL-
receptor activity of  liver cells  increases the clearance of  LDL-
cholesterol.
2. Both drugs effectively reduce LDL-cholesterol but can aggravate
hypertriglyceridaemia.
3. They can be offered as an alternative for primary and secondary
prevention  to  patients  where  statins  are  not  tolerated  or
contraindicated.
Plant Sterols and Stanols
NICE do not recommend that these are prescribed routinely for
the primary prevention of CVD.21 Although sterols and stanols have
been shown to reduce total cholesterol, further research is required to
demonstrate whether this translates into a reduction in CVD.
Monitoring Treatment22
Lipid  levels  should  be  monitored  periodically  after  starting
treatment.  No  data  support  specific  monitoring  intervals,  but
measuring  lipid  levels  2  to  3  months  after  starting  or  changing
therapies, and once or twice yearly after lipid levels are stabilized is
common practice.
Despite the low incidence of liver and muscle toxicity with statin
use (0.5 to 2% of all users), current recommendations are for baseline
measurements of liver and muscle enzyme levels at the beginning of
treatment.  Many  practitioners  obtain  at  least  one  additional  set  of
liver enzymes 4 to 12 week after beginning treatment and annually
thereafter.
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Statin therapy can be continued unless liver enzymes increase
to > 3 times the upper limit of normal. Muscle enzyme levels checking
is  not  needed  regularly  unless  patients  develop  myalgias  or  other
muscle symptoms. If muscle damage is suspected, statin use should
be stopped and CK can be measured. When symptoms go down, a
lower dose or a different statin can be tried.
Notes23
1. Combinations  of  a  statin  with  an  anion  exchange  resin,
nicotinic acid or a fibrate carry an increased risk of side-effects
(including rhabdomyolysis) and NICE does not recommend them
for the primary prevention of CVD.
2. NICE  considers  that  the  case  for  the  cost  effectiveness
(including  adverse  events)  of  higher  intensity  statins  (either
alone or in combination with other classes of drug) to reduce
CVD events by treating to  target  levels  of  total  cholesterol  of
either 5 mmol/L or 4 mmol/L (or comparable LDL cholesterol
levels) has yet to be proved.
Complications24
1. About 46% of deaths due to coronary heart disease (CHD) may
be attributable to raised serum cholesterol.
2. People with heterozygous familial hypercholesterolaemia have a
four-fold increased risk of CHD.
3. People  with  familial  combined  hyperlipidaemia  also  have  an
increased risk of CHD, but CHD usually only presents after the
age of 60 years.
4. Untreated  very  severe  hypertriglyceridaemia  (more  than  10
mmol/L) is a risk factor for pancreatitis.
5. Decreased levels of serum HDL cholesterol (HDL-C) are also an
independent risk factor for CHD.
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Indications for Referral25
These include:
1. Suspected familial hypercholesterolaemia: TC greater than 7.5
mmol/L (or LDL-C greater than 4.9 mmol/L) and at least one of
the following:
a. Tendon xanthomata in patient or in a first- or second-
degree relative.
b. Family history of premature CHD.
c. Family history of TC greater than 7.5 mmol/L.
2. Suspected  familial  combined  hyperlipidaemia26,  i.e.  mixed
hyperlipidaemia  and  a  family  history  of  hyperlipidaemia  or
premature CHD.
3. Failure of therapy: failure to meet target lipid reduction despite
maximally tolerated therapy.
4. Severe  hypercholesterolaemia:  initial  TC  greater  than  10
mmol/L.
5. Very severe hypertriglyceridaemia: triglycerides greater than 10
mmol/L.
The Other Side of Statins
Clinical  studies  and  epidemiological  analysis  established  the
relationship between high cholesterol level, atherosclerosis, and CVD.
Therefore, reducing the level of cholesterol decreases susceptibility to
CVD, and in high risk individuals, prolongs life.
3-Hydroxy-3-methylglutaryl  coenzyme A (HMG-CoA)  reductase
inhibitors27 (statins)  constitute  a  new  class  of  cholesterol-lowering
drugs.  They  competitively  inhibit  the  enzyme  HMG-CoA reductase,
which catalyzes the rate-limiting step in cholesterol biosynthesis, that
is, the conversion of HMG-CoA to mevalonate. In the blood, cholesterol
circulates attached to low density lipoprotein (LDL) particles, whose
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function  is  to  provide  cells  with  cholesterol.  The  statin-induced
inhibition of HMG-CoA reductase is thought to decrease the cellular
cholesterol  content  and  thus  to  stimulate  the  production  of  LDL
receptors.  This,  in  turn,  leads  to  an  increased  cellular  uptake  of
circulating  LDL  particles  and  ultimately  to  lower  total  serum
cholesterol and LDL cholesterol levels.
Undermining this advancement is the proverbial “other side of
the coin.”28. Mevalonate is the precursor not only of cholesterol, but
also  of  many  nonsteroidal  isoprenoid  compounds  vital  to  diverse
cellular functions, including cell proliferation.Fig.1 shows that.
These  isoprenoids  include dolichols,  required  for  glycoprotein
synthesis  and  coenzyme  Q  10,  involved  in  intracellular  electron
transport  and  energy  generation.  Thus,  while  inhibition  of  the
mevalonate  pathway  suppresses  cholesterol  production;  it  also
reducesCoQ bioavailability, causing CoQ deficiency.
It is now well established that oxidative stress resulting from the
formation of  intracellular  or  extracellular  free  radicals  and reactive
oxygen species 
(ROS)  is  a  major  factor  in  the  pathogenesis  of  CVD.  More
specifically,  oxidized  cholesterol  has  deleterious  effects,  including
carcinogenicity,  mutagenicity,  and  initiation  or  acceleration  of  the
atherosclerotic  process.  However,  systems  undoubtedly  exist  to
protect LDL-cholesterol particles in the blood from oxidative damage.
Attention has mostly been directed at fat-soluble antioxidants, such
as  alpha-tocopherol,  beta-carotene  and  coenzyme  Q,  which  are
present  in  LDL in  quantities  that  can be  modified  by  dietary  food
intake  or  oral  supplementation.  Clearly,  the  depletion  of  CoQ  by
statins is a serious clinical concern, since this depletion can initiate or
intensify LDL-cholesterol oxidation.
Department of Pharmacy Practice, K.M. College of Pharmacy, Madurai Page 37
                                                                                                                         Introduction
Fig. 1. Reaction Pathway Of The Biosynthesis Of
Cholesterol, Coenzyme Q10 (Ubiquinone)and Dolichols
In  his  book  ‘The  Antioxidant  Miracle’, Packer  wrote  that
antioxidants  function  better  in  a  coordinated  manner  with  one
another, which he calls the “antioxidant network”. In particular, the
interaction of CoQ with vitamin E is critical to the overall antioxidant
defence and has important clinical ramifications.
Coenzyme Q10 (Ubiquinone)
Coenzyme  Q  (coenzyme  Q10  or  CoQ10  in  humans,  (2,  3-
dimethoxy-5-methyl-6-decaprenyl-1,  4-benzoquinone)  is  a  naturally
occurring,  fat-soluble  nutrient,  with  characteristics  common  to
vitamins and, like vitamins, is essential for the optimal functioning of
an  organism.  CoQ  was  discovered  in  1957  by  Crane  and  his
associates  as  a  component  of  beef  heart  mitochondria.  In  1958
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Folkers and his associates determined its chemical structure.  Peter
Mitchell was awarded the Nobel Prize in Chemistry in 1978 for his
elucidation of the “Q-cycle.’’
The  essential  role  of  CoQ  for  cellular  energy  production  in
eukaryotes is well established. A vital electron and proton carrier, CoQ
supports adenosine triphosphate (ATP) synthesis in the mitochondrial
inner  membrane  and  stabilizes  cell  membranes,  thus  preserving
cellular  integrity  and  function.  CoQ10  is  a  potent  and  versatile
antioxidant that blocks oxidative injuries to DNA, lipids, proteins, and
other essential molecules. This well-documented function prevents or
retards  the  development  of  many  cardiovascular,  neoplastic,  and
probably neurodegenerative diseases.
Several  publications  illustrate  how,  diet-derived  antioxidants
participate in protection against these diseases. It has been reported
that the normal level of CoQ in mitochondrial  membranes is below
that  required for  kinetic  saturation.  This  finding  strongly  indicates
that CoQ might be a rate-limiting component in the respiratory chain,
especially in the mitochondria of injured Tissues.
The biosynthesis of CoQ is an elaborate 17-step process, first
described by Folkers that requires the availability of several vitamins
or  their  coenzyme  forms:  vitamins  B2,  B6,  B12,  C,  folic  acid,
niacinamide,  pantothenic  acid,  as  well  as  many  trace  elements.
Deficiencies of one or more of these building blocks will result in CoQ
deficiency, with subsequent impairment of certain vital functions. The
clinical  manifestations  of  CoQ  deficiency  are  diverse  and  are
determined  by  the  cells  and  organs  involved.  Additionally,  an age-
dependent decline of CoQl0 level is postulated to be responsible, in
part, for the diseases of aging. Bioenergetic degradation resulting from
CoQ10 deficiency affects first and most intensely the cardiovascular
and  immune  systems,  whose  cells  and  organs  place  the  highest
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energy demands of all body systems. Working with suboptimal energy,
a cascade of  functional impairment begins in these systems, as do
overt  clinical  manifestations.  Not  surprisingly,  cardiovascular  and
neoplastic  diseases  are the most  common causes  of  morbidity  and
mortality in the elderly.
Interest in the use of antioxidants for prevention and treatment
of  human  diseases  has  been  sustained  for  at  least  two  decades.
Developments  in  both therapeutic  and nutritional  fields  have  been
punctuated by successes and some failures. It is important to note
that in his book on CoQ10, Littarru devoted 71% of the content to the
CoQ10 defence against oxidative damage.
In conclusion, CoQ10 is an essential  nutritional factor,  not a
drug. This indisputable fact, unfortunately, hinders its acceptance by
most  conventional  clinicians  despite  the  reported  clinical  and
experimental results.
Dolichols
Proteins, those magic particles so important to our function and
destiny,  are  synthesized within the  membranes  of  the endoplasmic
reticulum (ER),  a  tubular  marvel  of  complexity  within  each  of  our
cells.29
It  is  within  this  microscopic  structure  that  amino  acids  are
linked together into a popcorn string-like peptide. Some peptides will
ultimately serve for cell identification so they may wander about our
immune  system  without  being  challenged;  others  produce  insulin
because our blood sugar is rising.
This class of proteins contains a signal as a recipe to guide the
ER  assembly  of  our  necessary  peptide,  thereby  matching  our
immediate needs. This entire process is orchestrated by dolichols in
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the  form of  dolichol  phosphate.  In  terms  of  chain  of  command,  it
cannot be told who issues the command for a certain peptide, for that
is  beyond our  understanding  at  this  time,  but the  command once
given is carried out by dolichol, the executive officer of this amazing
process.  We  are  dealing  with  a  factory  producing  a  substance,
assembly-line  fashion,  under  an  administration process  familiar  to
any production line facility.This peptide assembly process is greatly
disturbed by statin drug use.
During the congregation of the peptide strand within the ER,
sugars are added thereby converting the product into glycoproteins.
The  sugars  usually  found  in  glycoproteins  are  glucose,  galactose,
mannose, fucose, N-acetyl galactosamine, N-acetyl glucosamine and
N-acetyl neuraminic acid. The most recurrently found sugar in this
course  is  mannose.  Their  role  is  to  broaden  the  versatility  of  the
evolving  protein  structure  by  designating  points  and  direction  of
protein folding.
The  ultimate  role  depends  on  the  protein  structure.  Just
utilizing proteins can give hundreds of  options but the addition of
these  sugars  to  the  protein  strand  gives  tens  of  thousands  of
structural  options.  It  is  this  almost  boundless  range  of  structural
options  that  gives  humans  our  incredible  range  of  behavioral  and
emotional reactions. This progression, too, is orchestrated by dolichols
in its groundwork of the final protein structure.
   
This  dolichol-mediated  route  is  involved  in  neuropeptide
configuration and cell communication, cell identification and immune
system functions. This intricate role is such that almost anything can
be  expected  when  dolichols  are  deficient.  Altered  emotional  and
behavioral reactions associated with statin use are likely explained by
misrepresented neuropeptide formation. 
Department of Pharmacy Practice, K.M. College of Pharmacy, Madurai Page 41
                                                                                                                         Introduction
The  reality  of  dolichol  inhibition  by  Statins  is  certainly
documented.  The  role  of  dolichols  in  the  process  of  glycoprotein
synthesis is also systematically documented.
Dolichyl Phosphate Phosphatase (dolichyl pp)
Apart  from blocking  the  biosynthesis  of  coenzyme Q 10  and
dolichols, statins also block Dolichyl PP production. In enzymology,30
dolichyl-phosphatase  (EC  3.1.51)  is  an  enzyme  that  catalyses  the
chemical reaction.
Dolichyl Phosphate + H2O Dolichol + Phosphate
Thus, the two substrates of this enzyme are dolichyl phosphate
and H2O, whereas its two products are dolichol and phosphate.
Since statin therapy disturbs the biosynthesis of coenzyme Q10,
dolichols,  and  dolichyl  pp  these  products  are  to  be  supplemented
along with statin therapy, to cope up with their deficiencies, to ensure
normal functioning of the body.
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DRUG PROFILE
VITAMIN E[68]
Vitamin E  is  a  generic term for  tocopherols and  tocotrienols.
Vitamin  E  is  a  family  of  α  ,  β,  γ,  and  δ  -  tocopherols and
corresponding four tocotrienols. Vitamin E is a fat-soluble antioxidant
that stops the production of reactive oxygen species formed when fat
undergoes oxidation. Of these, α-tocopherol has been most studied as
it has the highest bioavailability. 
Chemically  it  is  (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-
trimethyltridecyl]- 3,4-dihydrochromen-6-ol. It is a Light yellow color,
odourless  substance   with  the  molecular  formula  C29H50O2 .  Its
Molecular  weight  is  430.7061  g/mol.  The  structural  formula  is
represented below:
Sources:
Vitamin E is found in variety of foods including Fortified cereals,
Green leafy vegetables,  Tomato products, Rockfish, Papayas, Seeds,
Nuts, Olives, Corn, Asparagus, and Vegetable oils.
Available brands:
Evion (200 mg, 400 mg & 600 mg), E- CAP (200 mg & 400 mg),
Ephynal (200 mg & 400 mg), Evitam (200 mg & 400 mg), Evitop (400
mg), Tocofer (200 mg & 400 mg) and Viteolin (200 mg & 400 mg). 
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Pharmacological classification:
Vitamins & Minerals (Fat – Soluble); Antioxidants.
Indications[69]:
 Alzheimer's Disease 
 High blood pressure during pregnancy (pre-eclampsia)
 Premenstrual syndrome (PMS)
 Macular Degeneration 
 Cancer Risk Reduction
 In premature infants exposed to high concentration of oxygen
 Vitamin E deficiency
 Nocturnal muscle cramps
 Fibrocystic breast disease 
 Coronary artery disease.  
Dosage and administration: 
Administration:
Usually administered orally; may administer parenterally as a 
component of a multivitamin injection.
Dosage:
Vitamin E deficiency:
Adult: 40-50 mg/day
Child: Neonate: 10 mg/kg/day; 1 month –18 yr: 2–10 mg/kg/day, up 
to 20 mg/kg
Supplementation in cystic fibrosis:
Adult: 67-135 mg/day. 
Child: As α- tocopheryl acetate: 1 month –1 yr: 50 mg/day; 1–12 yr:
100 mg/day; 12–18 yr: 200 mg once daily. Dose to be adjusted as
needed.
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Abetalipoproteinaemia:
Adult: 33-67 mg/kg/day.
Child: Neonate: 100 mg/kg/day; 1 mth–18 yr: 50–100 mg/kg/day.
Clinical Pharmacology:
Mechanism of Action
Vitamin E reacts with free radicals and protects RBCs against
haemolysis and PUFA’s in membranes against free radical attack.
Pharmacodynamics[70]:
Although all forms of Vitamin E exhibit antioxidant activity, it is
known that the antioxidant activity of vitamin E is not sufficient to
explain the vitamin's biological activity. Vitamin E's anti- atherogenic
activity  involves  the  inhibition  of  the  oxidation  of  LDL  and  the
accumulation  of  oxLDL  (Oxidized  LDL)  in  the  arterial  wall.  It  also
appears  to  reduce  oxLDL-induced  apoptosis  in  human  endothelial
cells.  Oxidation  of  LDL  is  a  key  early  step  in  atherogenesis  as  it
triggers  a  number  of  events  which  lead  to  the  formation  of
atherosclerotic plaque. In addition, vitamin E inhibits Protein Kinase
C (PKC) activity. PKC plays a role in smooth muscle cell proliferation,
and, thus, the inhibition of PKC results in inhibition of smooth muscle
cell  proliferation,  which  is  involved  in  atherogenesis.  Vitamin  E's
antithrombotic  and  anticoagulant  activities  involves  the
downregulation  of  the  expression  of  Intracellular  Cell  Adhesion
Molecule  (ICAM)-1  and  Vascular  Cell  Adhesion  Molecule  (VCAM)-1
which lowers the adhesion of blood components to the endothelium.
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Pharmacokinetics:
Absorption
20-80%  absorbed  from  gastrointestinal  tract.  Absorption
depends on the presence of bile and on normal pancreatic function;
decrease with increasing dose. 
Distribution 
Readily distributed into all tissues and stored in adipose tissue.
Crosses the placenta. Distributed into human milk.
Metabolism
Extensively  metabolized  in  the  liver,  to  glucuronides  of
tocopheronic acid and its γ-lactone.
Excretion
Excreted  principally  in  the  feces  via  biliary  excretion;  also
excreted in urine.
Cautions: 
Abdominal pain,  blurred vision, breast enlargement,  dizziness,
diarrhea,  influenza-like  symptoms,  headache,  nausea,  tiredness,
weakness. 
Mortality 
Long-term administration (>1 year) of high doses of vitamin E
(≥400 units daily) may increase all-cause mortality. 
Specific Populations: 
Pregnancy
Category A. 
Lactation 
Distributed into human milk. 
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Adverse drug reactions:
Hypertension, thrombophloebitis, myopathy, nausea, diarrhoea,
abdominal  pain,  Intestinal  cramping,  Fatigue,  weakness,  headache,
dizziness, Blurred vision, Any unusual bruising or bleeding, Signs of
gastrointestinal bleeding. Topical: Contact dermatitis. 
Drug interactions: 
Anticoagulants: 
Risk of hemorrhage with large doses of vitamin E. 
Iron supplements: 
Vitamin E dosages ≥10 units/kg daily may delay response to
iron therapy in children. 
Mineral oil: 
Possible impaired absorption of vitamin E. 
Orlistat: 
Possible impaired absorption of vitamin E. 
Others:
Drugs  such  as  antacids,  Cholestyramine,  Colestipol  may
decreases the absorption of Vitamin E.
Storage: 
Do not freeze. Store in a cool, dry place away from direct light. 
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COENZYME Q 10
Other Names: CoQ10,  Q  10,  Ubiquinone,  Ubiquinol  10,
Ubidecarenone, Vitamin Q 10.[71]
Class: Vitamin-like nutrient, heart energizer, strong antioxidant
Dose: 30 mg -300 mg/day[72]
Route of Administration: Oral and I.V.
Mechanism of Action:
CoQ10 is a fat-soluble substance and therefore it is absorbed
like any other fat in our diet. Digestion releases dietary CoQ10 from
the food matrix. CoQ10 supplements that are based on pure CoQ10
may  not  require  gastric  digestion.In  the  small  intestine,  secretions
from  the  pancreas  and  bile  enables  emulsification  and  micelle
formation that are inevitable for the absorption of fats along the small
intestine. No “active” transport mechanism is there for the absorption
of fats. Once CoQ10 is absorbed by the intestinal mucosal cells, it is
transported through the lymphatic system as part of the chylomicrons
and eventually taken up by the liver for repackaging into lipoprotein
particles and rereleased into the circulation.[73]
CoQ10 is present in all tissues in our body. In blood it is linked
with lipoproteins. The concentrations fluctuate from tissue to tissue.
Heart, muscle, liver, kidney and brain which are with high rates of
metabolic activity  and high energy demands contain relatively  high
concentrations of CoQ10. The state of CoQ10 (oxidized vs. reduced,
i.e. ubiquinone vs. ubiquinol) also varies from tissue to tissue, and
tissues with high aerobic activity generally contain higher amounts of
the oxidized form. In circulation, CoQ10 is present predominantly as
ubiquinol). The ratio of oxidized to the reduced form in blood is related
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to oxidative stress. Recent studies shows that the level of circulating
CoQ10  tends  to  decline  in  certain  disease  conditions,  such  as
diabetes, liver disease, down syndrome, etc.
                              
Coenzyme Q 10 is a fat-soluble substance. It is well absorbed
when taken along with fatty diet. So it was given in the form of soft
gelatin capsules filled with olive oil or soy bean oil in which Coenzyme
Q 10 was dissolved.
Indications
Cardiovascular disease  :  Cardiomyopathy, Congestive heart failure,
Angina  pectoris,Arrhythmias,  Mitral  valve  prolapse,  Hypertension,
Atherosclerosis, Cardiotoxicity (drug induced)
Neurodegenerative  diseases: Huntington’s  Disease,  Parkinson’s
Disease,  Alzheimer’s  Disease,  Amyotrophic  lateral  sclerosis  (Lou
Gehrig’s Disease).
Neuromuscular  diseases:  Mitochondrial  cytopathies  (MELAS,
MERRF,  etc.)  and  Muscular  dystrophy,  Ataxias,  Diabetes,  Cancer,
Chronic  obstructive pulmonary disease, Asthma, Migraine,  Immune
disorders, HIV/AIDS, Periodontal disease, Chronic fatigue syndrome
and Male infertility.71
Drug Interactions
If  you  are  currently  being  treated  with  any  of  the  following
medications, you should not use CoQ10 without first talking to your
health care provider.
Daunorubicin and doxorubicin72 - Coenzyme Q10 may help to reduce
the  toxic  effects  on  the  heart  caused  by  daunorubicin  and
doxorubicin, two chemotherapy medications that are commonly used
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to  treat  several  kinds  of  cancer.  Get  your  oncologist  advice  before
taking antioxidants along with chemotherapy.
Blood pressure medications - In a clinical study of individuals taking
blood pressure medications, including diltiazem, metoprolol, enalapril,
and  nitroglycerin.CoQ10  supplementation  to  the  individuals  made
them to take lower dosages of these drugs. As per this study, CoQ10
may enhance the effectiveness of certain blood pressure medications,
but more research is needed to verify these results.
Blood-thinning medications - CoQ10 chemically resembles vitamin
K.  Since  vitamin  K  counters  the  anticoagulant  effects  of  warfarin
(Coumadin), it is said that CoQ10 may have the same effect. But, a
small, double-blind study found no interaction between CoQ  10 and
warfarin.There have been reports that coenzyme Q10 may decrease
the effectiveness of  blood-thinning medications such as warfarin or
clopidigrel,  leading to the need for  increased doses.  Therefore,  this
medication  must  be  monitored  very  closely  for  maintenance  of
appropriate levels and steady blood thinning. CoQ10 should be used
with warfarin only under careful medical supervision.
Timolol - CoQ10 supplementation may reduce the heart-related side
effects  of  timolol  drops,  a  beta-blocker  medication  used  to  treat
glaucoma, without decreasing the effectiveness of the medication.
Other - Medications that can lower the levels of coenzyme Q10 in the
body  include  statins  for  cholesterol  ,  including  atorvastatin,
lovastatin,  pravastatin,  and  simvastatin,  fibric  acid  derivatives  for
cholesterol,  including  gemfibrozil,  beta-blockers  for  high  blood
pressure, such as atenolol, labetolol, metoprolol, and propranolol, and
tricyclic antidepressant medications, including amitriptyline, doxepin,
and imipramine.
Nutrient Interactions
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Coenzyme Q 10 plays a critical role in maintaining our supply of
vitamin  E.  When  vitamin  E  gets  "used  up",  coenzyme  Q  10  can
"recharge" it, and restore its antioxidant capability.73
Contra-indications
Pregnancy, lactation, young children, patients with severe liver
or kidney disease.
Side Effects:
In general, CoQ 10 appears to be extremely safe. No significant
side effects have been found, even in year long studies. The side effect
reported is mild transient nausea. No toxicity has been found, even at
high doses, in animals or humans. No serious side effects have been
reported  from  the  use  of  coenzyme  Q10.74 Some  patients  using
coenzyme Q10 have  experienced  mild  insomnia  (inability  to  sleep),
elevated levels of liver enzymes, rashes, nausea, and upper abdominal
pain.  Other  reported  side  effects  have  included  dizziness,  visual
sensitivity to light, irritability, headache, heartburn, and fatigue.
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ATORVASTATIN
Class:  HMG-CoA Reductase Inhibitors
Mechanism of Action: 
Atorvastatin is an oral drug that lowers the level of cholesterol
in the blood. It belongs to a class of drugs referred to as statins, which
includes  lovastatin,  simvastatin,  fluvastatin,  and  pravastatin.  All
statins, including atorvastatin, prevent the production of cholesterol
in the liver by blocking HMG-CoA reductase, an enzyme that makes
cholesterol. Statins reduce total cholesterol as well as LDL cholesterol
in blood. LDL cholesterol is believed to be the "bad" cholesterol that is
primarily responsible for the development of coronary artery disease.61
Reducing  LDL cholesterol  levels  retards  progression and  may  even
reverse coronary artery disease. Atorvastatin also reduces the level of
triglycerides  in  the  blood  and  raises  the  level  of  HDL  ("good")
cholesterol.  High  blood  concentrations  of  triglycerides  is  always
associated with coronary artery disease. Atorvastatin was approved by
the FDA in December 1996.
Dose:
Atorvastatin is prescribed once daily. The usual beginning dose
is 10 to 20 mg per day, and the maximum dose is 80 mg per day.
Individuals who need more than a 45% reduction in LDL cholesterol
may be started at 40 mg daily.[74] Atorvastatin may be taken with or
without food and at any time of day. 
Route of Administration: Oral
Indications:  Hyperlipidaemia,  hypertriglyceridaemia,
hypercholesterolaemia.
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Drug Interactions: 
Reduced  elimination  of  atorvastatin  could  raise  the  levels  of
atorvastatin in the body and hike up the risk of muscle toxicity from
atorvastatin.  So,  atorvastatin  should  not  be  given  with  drugs  that
lowers its elimination. Examples of such drugs include erythromycin,
ketoconazole,  itraconazole,  clarithromycin,  telithromycin,
cyclosporine,  nefazodone,  and  HIV  protease  inhibitors  such  as
indinavir and ritonavir.[75]
Use  caution  if  the  following  drugs  are  combined  with
atorvastatin  because  serious  side  effects  such  as  muscle  injury
(myopathy)  infrequently  could  occur:  Fibrates  (e.g.,  Gemfibrozil,
Fenofibrate, e.t.c.), high-dose Niacin (1 gram or more per day). Before
using  this  medication,  tell  your  doctor  or  pharmacist  of  all
prescription  and  nonprescription/herbal  products  you  may  use,
especially of birth control pills, cholestyramine, clopidogrel, colestipol,
digoxin, HIV protease inhibitors (e.g., indinavir, ritonavir), other drugs
which affect  certain  liver  enzymes (CYP 3A4 substrates,  inhibitors,
and inducers such as amiodarone, cyclosporine, diltiazem, verapamil,
rifampin, St. John's wort, carbamazepine).
All Labeled Uses 
Arteriosclerotic  vascular  disease,  heterozygous
hypercholesterolemia,  homozygous  familial  hypercholesterolemia,
hypercholesterolemia,  hypertriglyceridemia,  mixed  hyperlipidemia,
myocardial  infarction  prevention,  prevention  of  cerebrovascular
accident,  primary  dysbetalipoproteinemia,  primary  prevention  of
coronary  heart  disease,  and  slow  progression  of  coronary  artery
disease[76]
Unlabeled Uses 
Prevention of transient ischaemic attack.
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Side Effects
Atorvastatin  is  usually  well-tolerated.  Minor  side  effects  like
constipation,  diarrhoea,  fatigue,  gas,  heartburn,  and  headache  are
known to occur.  Atorvastatin may cause liver  and muscle  damage.
Serious liver damage caused by statins is uncommon.
 
More frequently, statins cause abnormalities of liver tests, and,
so, periodic measurement of liver tests in the blood is recommended
for all statins. Abnormal tests generally come back to normal even if a
statin is continued, but if the abnormal test value is higher than three
times the upper limit of normal, the statin generally is stopped. Liver
tests should be done before initiation, at 12 weeks following initiation
of therapy and dose changes, and periodically thereafter. 
Inflammation  of  the  muscles  caused  by  statins  can  lead  to
serious  breakdown  of  muscle  cells  called  rhabdomyolysis.
Rhabdomyolysis causes the release of muscle protein (myoglobin) into
the blood, and myoglobin can cause kidney failure and even death.
When  given  alone,  statins  cause  rhabdomyolysis  in  less  than  one
percent  of  patients.  To  prevent  the  development  of  serious
rhabdomyolysis,  patients  taking  atorvastatin  should  contact  their
healthcare provider immediately if they develop unexplained muscle
pain, weakness, or muscle tenderness. 
Adverse Effects
Most Frequent: 
Abdominal  Pain  with  Cramps,  Constipation,  Dyspepsia,
Flatulence
Less Frequent:
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Allergic  Reactions,  Arthralgia,  Diarrhoea,  Dizziness,  Flu-Like
Symptoms, Headache Disorder, Nausea, Pain, Pharyngitis, Sinusitis,
Skin Rash.
Rare: 
Abnormal  Hepatic  Function  Tests,  Alopecia,  Amblyopia,
Anaphylaxis,  Anaemia,  Angina,  Anorexia,  Arthritis,  Bronchitis,
Bursitis,  Chest  Pain,  Colitis,  Conduction  Disorder  of  the  Heart,
Contact  Dermatitis,  Cramps  in  Legs,  Cystitis,  Drowsy,  Dry  Eye,
Dysgeusia,  Dyspnoea,  Ecchymosis,  Epididymitis,  Erythema
Multiforme, oesophagitis, Fainting, Fatigue, Fever, Fibrocystic Breast
Disease,  Gastroenteritis,  Gastrointestinal  Ulcer,  General  Weakness,
Gingival  Bleeding,  Glaucoma,  Gout,  Gynaecomastia,  Haematuria,
Hepatic  Failure,  Hepatitis,  Hyperglycaemia,  Hyperhidrosis,
Hypertonia,  Hypoglycaemic  Disorder,  Increased  Urinary  Frequency,
Insomnia, Kidney Stone, Libido Changes, Lymphadenopathy, Memory
Impairment, Metrorrhagia, Myalgia, Myopathy, Neck Stiffness, Ocular
Bleeding,  Orthostatic  Hypotension,  Palpitations,  Pancreatitis,
Paraesthesia, Peripheral oedema, Peripheral Neuropathy, Proteinuria,
Pruritus  of  Skin,  Rectal  Bleeding,  Rhabdomyolysis,  Rhinitis,  Skin
Photosensitivity,  Stevens-Johnson  Syndrome,  Stomatitis,  Tendon
Rupture,  Thrombocytopaenic  Disorder,  Tinnitus,  Toxic  Epidermal
Necrolysis, Urinary Tract Infections, Vomiting, Xerostomia
Contraindications
Most Significant 
Abnormal  Hepatic  Function  Tests,  Disease  of  Liver,  Hepatic
Failure, Lactating Mother, Pregnancy, Rhabdomyolysis.
Significant 
Alcoholism, Myopathy with CK Elevation, Severe Hypotension,
Severe Infection, Surgical Procedure, Trauma, Uncontrolled Epilepsy.
Possibly Significant 
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Haemorrhagic  Stroke,  Myalgia,  Renal  Disease,  Transient
Cerebral Ischaemia, Untreated Hypothyroidism.
Warnings
Pediatric
1. Safety  and  efficacy  under  10  years  of  age  and  in  pre-
menarche girls are not established.
2. Post-menarche females should be counseled on appropriate
contraception.
Lactation: Absolute Contraindication
Pregnancy: Absolute Contraindication
Geriatric 
Precaution: Myopathy, Rhabdomyolysis and Liver dysfunction.
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LITERATURE REVIEW
 Giuseppe Caso31 and his  colleagues  performed a  preliminary
study on the effect of coenzyme Q 10 on statin induced myalgia.
Patients with myopathic symptoms were randomly assigned in a
double-blinded protocol to treatment with coenzyme Q10 (100
mg/day, n _ 18) or vitamin E (400 IU/day, n _ 14) for 30 days.
Muscle  pain  and  pain  interference  with  daily  activities  were
assessed before and after treatment. After a 30-day intervention,
pain severity decreased by 40% (p <0.001) and pain interference
with daily activities decreased by 38% (p <0.02) in the group
treated with coenzyme Q10.  In contrast,  no  changes  in  pain
severity (_9%, p _ NS) or pain interference with daily activities
(_11%, p _ NS) was observed in the group treated with vitamin
E.  They  concluded  that  coenzyme Q10 supplementation  may
decrease muscle pain associated with statin treatment and so
coenzyme  Q10  supplementation  may  offer  an  alternative  to
stopping treatment with these vital drugs.
 Gazdikova-et-al32,  studied  the  effect  of  coenzyme  Q  10  in
patients with kidney disease. The study involved 15 patients in
which 5 had tubulopathy and 10 had chronic tubulointerstitial
nephritis. All the 15 patients received antioxidant therapy for 3
months with vitamin E, vitamin C, and riboflavin. And for the
last  2 months coenzyme Q 10 was added.  At  the end of  the
study  tests  for  renal  functions,  lipid  spectrum,  lipid
peroxidation parameters (malondialdehyde), and levels of alpha-
tocopherol, beta-carotene and coenzyme Q 10 were performed.
Coenzyme Q10 levels significantly increased (p < 0.001) to the
values of 1.66 +/- 0.16 mumol/l in blood and to 1.78 +/- 0.27
mumol/l  in  plasma.  Plasma levels  of  beta-carotene  increased
from the markedly subnormal values 0.25 +/- 0.07 mumol/l (rr
>  0.8  mumol/l)  to  0.56  +/-  0.02  mumol/l  (no  statistical
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difference).  Plasma levels of  alpha-tocopherol  remained within
the reference range 32.15 +/- 4.73 mumol/l (rr 15-30 mumol/l)
and they increased up to the plasma level  of  44.83 +/- 5.82
mumol/l  during the period of  testing.  Malondialdehyde levels
did not show a significant change within the testing period. No
deflections  in  renal  functions  and  parameters  of  lipid
metabolism  were  noticed.  Patients  tolerated  the  treatment
effectively and no adverse effects were seen during the period of
observation.Gazdikova  concluded  that  levels  of  antioxidant
CoQ10 were lower in patients with nephropathy who underwent
conservative treatment with peroral substation. Such shortage
can  be  amended  by  CoQ10  administration,  which  could  be
therefore taken as complementary treatment of nephrology.
 Kazuki Nukui33 and his coworkers studied the blood Co Q 10
levels  after  single  dose  or  chronic  administration  of  Water-
soluble type Co Q 10(puresorb-QTM 40). Single administration
revealed a higher absorption level for P40, taken in the fasting
state  or  together  with  meals.  In  this  double-blind,  placebo
controlled,  comparative  study  conducted  on  46  healthy
volunteers  are  randomly  divided  into  two  groups.  The  study
group received 900 mg of P40 for 4 weeks. The absorption of
P40 was very high which was revealed by the the plasma Co Q
10 levels at the end of the 4 weeks. P40 intake did not show any
significant deviations in symptoms and clinical laboratory tests
as  assessed by  physical,  hematological,  blood biochemical  or
urinalysis.  Clinical  examinations  also  did  not  disclose  any
abnormalities.
 Flint Beal34 and his colleagues studied the effect of coenzyme Q
10 on the striatal lesions produced by the mitochondrial toxin,
malonate. At the end of the one week study the lesions were
reduced in size and it was proved with the MRI in vivo. Finally,
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they suggested that the coenzyme Q 10 work by blocking the
ATP depletions and lactate increases.
 Munkholm-et-al35, Studied, by an invasive method, the effect of
Coenzyme Q 10 on serious heart failure.22 patients with mean
left  ventricular  (LV)  ejection  fraction  26%,  mean  LV  internal
diameter 71mm, and in NYHA class 2-3.The patients were given
coenzyme Q 10 100 mg twice daily or placebo for 12 weeks in a
randomized  double-blinded  placebo  controlled  investigation.
Before  and  after  the  treatment  period,  a  right  heart
catheterization was done including a 3 minute exercise test. At
the end of the 12 weeks study the stroke index at rest and work
improved significantly,  the pulmonary artery pressure  at  rest
and work decreased (significantly at rest), and the pulmonary
capillary  wedge  pressure  at  rest  and  work  decreased
(significantly  at  1  min work),which imply improvement  in  LV
performance.  Finally  they  concluded  Patients  with  congestive
heart failure may thus benefit from adjunctive treatment with
coenzyme Q10.
 Rosenfeldt-et-al36,  performed  a  meta-  analysis  on  the
antihypertensive effect of coenzyme Q 10 and found that some
trials documented statistically significant reductions in diastolic
or  systolic  blood  pressure  or  both,  while  others  reported
negligible  effects.  In one  small  trial,  blood pressures actually
went up in patients taking coenzyme Q10. Coenzyme Q10 doses
and duration of therapy varied from study to study in the meta-
analysis. Minor adverse effects such as GI upset and headache
were reported.
 Yamagami37 et  al,  studied  the  antihypertensive  effect  of
coenzyme  Q  10.They  randomly  assigned  20  patients  with
hypertension and a low coenzyme Q10 level to receive 100 mg of
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coenzyme Q10 or placebo daily for 12 weeks. Patients followed
their usual antihypertensive regimen during the study period.
Blood  pressures,  coenzyme  Q10  levels,  and  antihypertensive
drugs given were comparable between the  two study groups.
After 12 weeks of therapy, the mean coenzyme Q10 level in the
active-treatment group had more than doubled, from 0.704 to
1.597 µg/mL.This group also showed a statistically significant
drop in systolic blood pressure, from 167 mm Hg at baseline to
148 mm Hg at  12 weeks.  In the  placebo  group,  the  systolic
blood pressure dropped from 168 mm Hg at baseline to 164 mm
Hg at 12 weeks, but the change was not statistically significant.
Diastolic  pressure  also  did  not  go  down  significantly..  The
authors  concluded  that  coenzyme Q10  supplementation
induced a mild reduction in high blood pressure in patients who
had low coenzyme Q10 serum levels.
 Digiesi  et  al38,  randomized  18  patients  with  essential
hypertension to receive either coenzyme Q10 100 mg or placebo
daily for 10 weeks. All antihypertensive therapy was withdrawn
at baseline. After the first 10 weeks, patients went through a 2-
week washout period and then were given an opposite therapy
for an additional 10 weeks. Mean baseline blood pressure was
167/103  mm  Hg.  Those  taking  the  supplement  had  a
statistically  significant  decrease  in  systolic  and  diastolic
pressures (P < 0.001). The drop in blood pressure was noted in
the 3rd or 4th week of active treatment and persisted for the
duration of therapy. The effects debauched 7 to 10 days after
coenzyme Q10 was stopped.
 Langsjoen39 et al, evaluated the effects of adding coenzyme Q10
to the antihypertensive drug regimen of 109 patients who had a
primary  diagnosis  of  essential  hypertension  in  a  prospective
observational  study.  Patients  having  hypertension  as  a
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secondary diagnosis and other cardiovascular diseases were not
enrolled. Variable doses of coenzyme Q10 were given, adjusted
according  to  clinical  response  and  to  achieve  serum  levels
greater than 2.0 µg/mL. The average dose was 225 mg/day; the
mean  serum  level  attained  was  3.02  µg/mL.
Over  several  months,  patients  taking  the  supplement  had  a
reduction  in  mean  systolic  pressure  from  159  mm  Hg  at
baseline to 147 mm Hg (P  < 0.001). A drop in mean diastolic
pressure from 94 to 85 mm Hg (P < .001) was noticed. Thirty-
seven  percent  of  patients  were  able  to  discontinue  one
antihypertensive  drug,  11% discontinued  two drugs,  and 4%
were able to stop taking three drugs. However, 46% remained
on  the  same  antihypertensive  regimen,  and  3%  needed  an
additional drug.
 Singh-et-al40, randomized 64 patients who had coronary artery
disease and who had been on antihypertensive drugs for more
than 1 year to receive either B-complex vitamins or coenzyme
Q10 (hydrosoluble Q-Gel) 60 mg orally once daily for 8 weeks. 5
patients were not available for proceedings, so, only 59 patients
were monitored. Fifty-five (93%) of the 59 patients were taking
only  one  antihypertensive  drug.  Initial  antihypertensive  drug
use  was  similar  between  study  groups  and  was  continued
throughout the trial.  After  8 weeks of  therapy,  the coenzyme
Q10 group had significantly lower systolic and diastolic blood
pressure than the placebo group (P < 0.05 for both). There was
also  a  statistically  significant  decrease  in  the  dosage  of
antihypertensive drugs in the coenzyme Q10 group but not in
the placebo group (P < 0.05), reflecting coenzyme Q10’s additive
antihypertensive effect.
 Burke41,  randomized  41  men  and  35  women  with  isolated
systolic  hypertension  (systolic  pressure  150–170  mm  Hg,
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diastolic pressure < 90 mm Hg) to receive a twice-daily dose of
60 mg of emulsified coenzyme Q10 (hydrosoluble Q-Gel)  with
150 IU of vitamin E or placebo containing vitamin E alone for 12
weeks.  The  study  also  included  5  men  and  4  women  with
normal blood pressure, all of whom received coenzyme Q10. A
total of 80 patients completed treatment.  The primary goal of
the study was to determine the efficacy of coenzyme Q10 in the
treatment of isolated systolic hypertension in patients without
comorbid conditions. Blood pressures were monitored twice a
week during the  trial,  by the same nurse.  After  12 weeks of
treatment,  the  mean  reduction  in  systolic  pressure  in
hypertensive patients on coenzyme Q10 was 17.8 ± 7.3 mm Hg.
There were no significant changes in diastolic pressure in any
study  group  with  treatment.  Patients  with  isolated  systolic
hypertension who were taking coenzyme Q10 had a statistically
significant  reduction  in  systolic  pressure  compared  with
baseline and placebo (P < 0.01 for both). Approximately 55% of
patients  on  coenzyme  Q10  achieved  a  reduction  in  systolic
pressure of 4 mm Hg or greater, while 45% did not respond to
therapy. The mean plasma coenzyme Q10 level of the treatment
group increased from 0.47 ± 0.19 µg/mL to 2.69 ± 0.54 µg/mL
after 12 weeks; however, the study did not have the statistical
power  to  demonstrate  a  relationship  between  coenzyme  Q10
levels and changes in blood pressure. Twenty-seven (34%) of the
80  patients  were  taking  a  statin  while  on  coenzyme  Q10
therapy.
 Thibault  et-al42,  reported  that  patients  taking  lovastatin
(Mevacor) at dosages as high as 35 mg/kg/day to inhibit tumor
growth  achieved  symptomatic  relief  of  statin-induced
musculoskeletal toxicity after coenzyme Q10 supplementation.
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 Young et-al43 studied the effect of  coenzyme Q 10 on stating
induced  myopathy.  They  randomized  44  patients  with  prior
statin-induced  myalgia  to  receive  increasing  doses  of
simvastatin  (10–40  mg/  day)  in  combination  with  either
coenzyme Q10 (Q-Gel) 200 mg/day or placebo. The primary goal
was to determine if coenzyme Q10 supplementation would help
improve  statin  tolerance  in  patients  with  a  history  of
statininduced myalgia.  Plasma coenzyme Q10 and lipid levels
were measured at  baseline and at the end of  the study. The
intensity of myalgia was assessed with a visual analogue scale.
At 12 weeks, the coenzyme Q10 plasma level was significantly
higher in the treatment group than in the placebo group (P  <
0.001). However, no differences were noted between groups in
the  number  of  patients  who  tolerated  the  40-mg/day
simvastatin dose (P  = 0.34) or in the number of patients who
remained  on  any  simvastatin  dose  (P  =0  .47).  Additionally,
myalgia scores  did not  differ  between groups (P  = 0.63).  The
authors acknowledged that there were only small increases in
the  myalgia  pain  scores  reported  in  either  group.  Therefore,
patients  in  the  treatment  group  may  not  have  experienced
sufficiently severe muscle pain to have benefited from coenzyme
Q10 supplementation.
 Folkers44, studied the effect of coenzyme Q 10 on the Immune
function.  In  the  study  which  included  eight  chronically  ill
patients, administration of 60 mg/day of CoQ10 were associated
with significant increases in serum levels of immunoglobulin G
(IgG) after 27- 98 days of treatment. These studies suggest that
CoQ10  may  help  prevent  or  reverse  the  immunosuppression
that is associated with aging or chronic disease.
 Folkers-et-al45,  studied the effect  of  coenzyme Q 10 in AIDS
patients, in the blood levels of CoQ10 were significantly lower in
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patients  with  AIDS  related  complex  (ARC)  than  in  a  control
group, and were significantly lower in patients with AIDS than
in those with ARC. Six patients with AIDS or ARC were treated
with  200  mg/  day of  CoQ10.  T-cell  helper/suppressor  ratios
increased in three patients, becoming normal in one case. Five
patients  reported  symptomatic  improvement,  which  was
dramatic  in  some  cases.  Furthermore,  none  of  the  patients
developed opportunistic infections during a 4-7 month follow-up
period.  This  study  demonstrates  that  CoQ10  deficiency  is
common  in  patients  with  HIV  infection,  and  that
supplementation  with  CoQ10  may  improve  immune  function
and reduce the incidence of opportunistic infections.
 Lockwood  et-al46,  studied  the  effect  of  coenzyme  Q  10  in
Breast  cancer  patients  In  the  study,  32  women  with  breast
cancer  who were  classified  as  “high risk”  because of  tumour
spread  to  the  axillary  lymph  nodes  received  daily  90  mg  of
CoQ10,  along  with  vitamin  C,  vitamin  E,  beta-carotene,  and
essential fatty acids. In six of these cases, the tumour became
smaller.  During  the  18-month  treatment  period,  none  of  the
patients  died  (the expected number of  deaths  was four),  and
none showed signs of further distant metastases. Six patients
had  an  apparent  partial  remission.  In  addition,  patients
receiving  CoQ10  required  fewer  pain  killers.  In  1995,  he
performed another  study.  Two  women with  metastatic  breast
cancer received 390 mg/day of CoQ10. One of the patients was
a 44-  year-old  woman with  numerous liver  metastases.  After
treatment with CoQ10 for 11 months, all of the liver metastases
had disappeared and the patient was reported to be in excellent
health. The other patient was a 49-year-old woman with breast
cancer  that  had  metastasized  to  the  pleural  cavity.  After  six
months  of  CoQ10  therapy,  the  pleural  fluid  had  completely
resolved and the patient was reported to be in excellent health.
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Considering that CoQ10 is virtually free of side effects, empirical
treatment of breast cancer with CoQ10 seems justified.
 Wilkinson  et-al47,  studied  the  effect  of  coenzyme  Q  10  on
periodontal disease. In that open trial, administration of CoQ10
produced  “extraordinary  post-surgical  healing”  (2-3  times  as
fast as usual) in 7 patients with advanced periodontal disease.
In1976, he did another study in which eighteen patients with
periodontal disease received either 50 mg/day of  CoQ10 or a
placebo in a 3-week, double-blind trial. Results were assessed
according  to  a  “periodontal  score,”  which  included  gingival-
pocket depth, swelling, bleeding, redness, pain, exudates, and
looseness of teeth. All eight patients receiving CoQ10 improved,
compared to only three of ten receiving the placebo (p < 0.01).
 Van Gaal48, studied the effect of coenzyme Q 10 on Obesity. The
serum levels of CoQ10 were found to be low in 14 (52%) of 27
morbidly obese patients. Nine of these 27 individuals (five with
low CoQ10 levels) received 100 mg/day of CoQ10 along with a
650 kcal/day diet. After 8-9 weeks, the mean weight loss in the
CoQ10- deficient group was 13.5 kg, compared with 5.8 kg in
those with normal levels of CoQ10.
 Vanfraecchem et-al49, studied the effect of coenzyme Q 10 on
Physical performance. In the study, six healthy, sedentary men
(mean age, 21.5 years) performed a bicycle ergometer test before
and  after  taking  CoQ10  (60  mg/day)  for  4-8  weeks.  CoQ10
treatment improved certain performance parameters, including
work capacity at  submaximal heart  rate,  maximal  work load,
maximal  oxygen  consumption,  and  oxygen  transport.  These
improvements ranged from 3-12% and were evident after about
four  weeks  of  supplementation.  This  study  suggests  that
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administration  of  CoQ10  improves  physical  performance  in
sedentary individuals
 Folkers  et-al50,  studied  the  effect  of  coenzyme  Q  10  on
Muscular  dystrophy,  in  the  double-blind  study,  100  mg  of
CoQ10 was given daily  for  three months to  12 patients with
progressive muscular dystrophy. CoQ10 treatment resulted in
significant improvements in cardiac output and stroke volume,
as well as increased physical well being in four of eight patients.
Subjective improvements included increased exercise tolerance,
reduced leg pain, better control of leg function, and less fatigue.
The  mechanism  of  action  of  CoQ10  is  probably  related  to
improved energy production in muscle cells.
 Rozenet-al51, studied the Migraine preventive effect of coenzyme
Q 10. 32 patients (26 women, 6 men) with a history of episodic
migraine  with  or without  aura  were  treated  with  150 mg  of
coenzyme Q10 per day. 31 of 32 patients completed the study;
61.3% of patients had a greater than 50% reduction in number
of days with migraine headache. The average number of days
with  migraine during  the  baseline  period  was  7.34  and  this
decreased  to  2.95 after  3  months  of  therapy,  which  was  a
statistically significant response (P < 0.0001). Mean reduction in
migraine frequency after 1 month of treatment was 13.1% and
further, this increased to 55.3% at the end of 3 months. Mean
migraine attack frequency was 4.85 during the baseline period
and  this  decreased  to  2.81  attacks by  the  end  of  the  study
period, which was a statistically significant response (P < 0.001).
There were no side-effects noted with coenzyme Q10. From this
open label  investigation coenzyme Q10 appears  to  be  a  good
migraine preventive.
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 Teranet-al52, studied the effect of coenzyme Q 10 in pregnant
women. This  was  the  first  study  on  pregnant  women
supplemented  with  coenzyme  Q10.  Supplementation  of
Coenzyme Q 10 began at 20 weeks of pregnancy, and the dose
was  200  mg/day.  It  was  able  to  significantly  reduce  the
incidence  of  pre-eclampsia,  a  common  disorder  of  human
pregnancy  in  which  the  normal  haemodynamic  response  to
pregnancy  is  impaired.  This  is  a  leading  cause  of  maternal
morbidity and mortality and a significant increase in perinatal
mortality.  
 Safarinejad53 studied the  effect  of  coenzyme Q 10  on semen
parameters,  sperm  function  and  reproductive  hormones  in
infertile men. In this study 212 infertile men were treated with
300 mg/day CoQ10 or placebo for 26 weeks.They were having
idiopathic  oligoasthenoteratospermia.  In  the  CoQ10
group,sperm  count  and  motility  values  showed  a  significant
improvement. Serum FSH and LH decreased significantly at the
26  week  treatment  phase.  As  the  serum  FSH  was  low,
spermatogenesis  was  considered  to  have  improved.  Moreover
Inhibin B, which reflects Sertoli’s cell function, increased in the
CoQ10 group.
 Kocharianet-al54,  studied  the  effect  of  coenzyme  Q  10  on
diastolic  function  in  children  with  idiopathic  dilated
cardiomyopathy This is one of the few papers where CoQ10 was
given, (from 2 to 10 mg/kg/day, for 6 months) in a double blind
trial,  to  a  group  of  children  affected  by  idiopathic  dilated
cardiomyopathy.  Index  of  heart  failure  showed  a  significant
improvement.  Myocardial  performance  index  also  showed  a
significant improvement.
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 Hamilton55  studied the effect of coenzyme Q 10 on endothelial
dysfunction in statin-treated type 2 diabetic patients This study
is  consistent  with previous reports  on the vascular effects  of
CoQ10.  There was a significant increase Flow Mediated Dilation
(FMD) in type 2 diabetic patients on stable statin therapy, who
received 200 mg CoQ10/day for 12 weeks.
 Kenji-et-al56 of Japan studied the safety profile of coenzyme Q
10(Kaneka  Q  10).It  was  double-blind,  randomized,  placebo-
controlled study. Coenzyme Q10 in capsule form was taken for
4 weeks at doses of 300, 600, and 900 mg/day by a total of 88
adult volunteers. No serious ADRs were observed in any group.
But were reported in 16 with placebo, in 12 with the 300 mg , in
20 with the 600 mg, and in 16 volunteers with the 900 mg dose.
Common cold  symptoms and  gastrointestinal  effects  such as
abdominal pain and soft faeces were reported. Changes seen in
blood data and biochemical data showed that Kaneka Q10 was
well-tolerated and safe for healthy adults till a dose of 900 mg.
 Yeutsu  Ihara  et-al57 studied  the  effect  of  coenzyme  Q  10
mitochondrial encephalomyopathy (MELAS). Two patients with
mitochondrial  myopathy,  encephalopathy,  lactic  acidosis  and
stroke  like  episodes  (MELAS)  in  one  family  are  reported.
Pathological  examination of  case  1  showed ragged-red  fibers,
with 7% of the fibers being unstained by cytochrome c oxidase
stain, peripheral nerve damage, multiple areas of softening in
the  cerebrum  and  midbrain,  and  spongy  changes  in  the
cerebrum,  optic  nerve  and  pons.  Electron  microscopic
examination showed abnormal accumulations of mitochondria
in  the  skeletal,  smooth  and  cardiac  muscle.  The  effect  of
cytochrome c oxidase on the brain and liver showed a decrease.
In a maternal  aunt of  case 1,  with coenzyme Q10,  muscular
weakness and peripheral nerve damage improved.
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 Soja et-al58, studied the effect of coenzyme Q 10 on congestive
heart  failure.  Meta-analysis  was  performed..  The  parameters
,measured  were  stroke  volume  (SV),  cardiac  output  (CO),
ejection fraction (EF), cardiac index (CI),  end diastolic volume
index (EDVI), systolic time intervals (PEP/LVET) and total work
capacity (Wmax). The supplemental treatment of CHF with CoQ10
is consistent with an improvement of SV, EF, CO, CI and EDVI.
Homogeneity was established for SV and CO.
 Dr. Shultz59, conducted a pilot study on the effect of coenzyme
Q 10 on patients with Parkinson’s disease, which showed that
consumption of up to 800 mg/day of coenzyme Q10 was well-
tolerated and significantly increased the level of coenzyme Q10
in  the  blood.  The  group  that  received  the  largest  dose  of
coenzyme Q10 (1,200 mg/day) showed 44 percent less decline
in mental function, ability to carry out activities of daily living,
such as feeding or dressing themselves and motor (movement)
function.  Daily  activities  improved.  Significant  increase  in
energy-producing  reactions  within  their  mitochondria  was
observed  in  the  groups  that  received  coenzyme  Q10.  The
authors concluded that a dose up to 1200mg/day is safe and
more effective than lower doses.
 Gaby-et-al60, studied the effect of coenzyme Q 10 on melanoma.
In  this  Non-randomized  trial  was  performed.400  mg  of
Coenzyme  Q  10  was  given  per  day  to  32  patients  who  had
surgically removed stage I or II melanoma for three years. 49
patients were in the controlled group. Recombinant interferon
alpha-2b was given throughout the trial to all patients. After five
years,  metastases  had  occurred  in  26.5% of  patients  in  the
control group and in 3.1% of those receiving CoQ10 (p = 0.006).
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 Victor VM et.al.  [61] have made an attempt for a potential new
therapeutic  strategy  for  cardiovascular  diseases  by  targeting
antioxidants  to  Mitochondria.  Mitochondria  produce  large
amounts of free radicals and play an important role in the life
and death of a cell. Thus, mitochondrial oxidative damage and
dysfunction  contribute  to  a  number  of  cell  pathologies  that
manifest  themselves  through  a  range  of  conditions  including
ischemia-reperfusion  injury,  sepsis,  diabetes,  atherosclerosis
and consequently cardiovascular diseases. In fact, endothelial
dysfunction,  characterized  by  a  loss  of  nitric  oxide  (NO)
bioactivity,  occurs  early  on  in  the  development  of
atherosclerosis, and determines future vascular complications.
This review considers the process of CVD from a mitochondrial
perspective.  In  this  review,  they  provide  a  summary  of  the
cellular metabolism of reactive oxygen species (ROS) and its role
in  pathophysiological  processes  such  as  CVD,  currently
available  antioxidants  and  possible  reasons  for  their  efficacy
and  inefficacy  in  ameliorating  oxidative  stress-mediated
diseases;  recent  developments  in  mitochondrially-targeted
antioxidants and their therapeutic potential for future treatment
of CVDs.   
 David G. Warnock et.al. [62]  studied that 18,722 participants in
the REGARDS (Reasons for Geographic and Racial Differences
in Stroke) Study, a population-based U.S. sample of individuals
aged 45 years and older. In this sample, 4,764 individuals had
CVD and 14,361 did  not.  CVD included previous myocardial
infarction,  stroke,  or  a  history  of  cardiovascular  procedures.
Among subjects with CVD and CKD, an estimated glomerular
filtration rate (eGFR) below 60 mL/min/1.73 m2 was associated
with  a  2.8  times  increased  risk  of  death  from  any  cause
compared  with  subjects  without  CKD  or  CVD.  Anemia  was
associated with a 2.7 times increased risk. Microalbuminuria
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was associated with a 2.6 times increased risk. Among subjects
with  CKD  but  not  CVD,  an  eGFR  below  60,  anemia  and
microalbuminuria increased the risk of  all-cause mortality by
46%, 70% and 80% respectively. 
 Armando Lindner, Bernard Charra et.al. [63] have studied the
survival  experience of  39 patients receiving long-term regular
hemodialysis  with  particular  reference  to  mortality  and
morbidity  from  arteriosclerotic  cardiovascular  complications.
Mean age (± 1 S.D.) was 37.0 ± 9.5 years for the group at the
start  of  dialysis.  Mean  duration  of  treatment  was  6.5  years.
Overall mortality was 56.4% at the end of the 13-year follow-up
period,  and  14  of  23  deaths  could  be  attributed  to
arteriosclerotic complications: MI was responsible for 8, strokes
for 3, and refractory congestive heart failure for 3 deaths. The
incidence of these complications was many times higher than
for  normal  and  hypertensive  groups  of  comparable  age,  and
similar  to  rates  found in  Type  2 hyperlipoproteinemia.  These
results indicate that accelerated atherosclerosis is a major risk
to long-term survivors on maintenance hemodialysis.   
 Emma A. Meagher et.al. [64]   have conducted a Randomized,
double-blind, placebo-controlled trial with 30 healthy men and
women aged 18 to 60 years to assess the effects of supplemental
vitamin  E  on  lipid  peroxidation  in  vivo  in  healthy  adults.
Participants  were  randomly  assigned to receive placebo or  a-
tocopherol dosages of 200, 400, 800, 1200, or 2000 IU/d for 8
weeks  (n=5  in  each  group),  followed  by  an  8-week  washout
period.  Three  indices  of  lipid  peroxidation,  urinary  4-
hydroxynonenal (4-HNE)  and  2  isoprostanes,  iPF2α-III  and
iPF2α –VI were and compared among the 6 groups at baseline,
2,  4,  6,  and  8  weeks,  and  1,  3,  and  8  weeks  after
discontinuation. The results concludes the rationale for vitamin
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E supplementation in healthy individuals. Specific quantitative
indices of oxidative stress in vivo should be considered as entry
criteria  and for dose selection in clinical  trials of  antioxidant
drugs and vitamins in human disease. 
 Herrera E et.al. [65] have reviewed the action, metabolism and
perspectives of Vitamin E. As vitamin E acts in cell membranes
where it  prevents the propagation of  free radical  reactions, it
has been also shown to have pro-oxidant activity. Non-radical
oxidation  products  are  formed  by  the  reaction  between  α-
tocopheryl radical and other free radicals, which are conjugated
to glucuronic acid and excreted through the bile or urine. In
Liver, By the action of the "alpha-tocopherol transfer protein", a
major  proportion  of  alpha-tocopherol  is  incorporated  into
nascent  very  low  density  lipoproteins  (VLDL),  whereas  the
excess of alpha-tocopherol plus the other forms of vitamin E are
excreted in bile. Once secreted into the circulation, VLDL are
converted into IDL and LDL by the action of Lipoprotein Lipase
(LPL), and the excess of surface components, including alpha-
tocopherol, are transferred to HDL. Besides the LPL action, the
delivery of alpha-tocopherol to tissues takes place by the uptake
of  lipoproteins  by  different  tissues  throughout  their
corresponding receptors.  
 Wang  X et.al. [66] reviewed  the  function  of  Vitamin  E  in
membranes.  Due to its lipophilic  properties,  it  partitions into
lipid  storage  organelles  and  cell  membranes.  It  is,  therefore,
widely distributed in throughout the body. Vitamin E is believed
to  be  involved  in  a  variety  of  physiological  and  biochemical
functions.  The  molecular  mechanism  of  these  functions  is
believed to be mediated by either the antioxidant action of the
vitamin or by its action as a membrane stabiliser. α -Tocopherol
is an efficient scavenger of lipid peroxyl radicals and, hence, it is
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able  to  break  peroxyl  chain  propagation  reactions.  The
regeneration of α -tocopherol from its tocopheroxyloxyl radical
greatly enhances the turnover efficiency of α-tocopherol in its
role as a lipid antioxidant. The molecule is able to rotate about
its long axis and diffuse laterally within fluid lipid bilayers. The
vitamin does not distribute randomly throughout phospholipid
bilayers  but  forms  complexes  of  defined  stoichiometry  which
coexist with bilayers of pure phospholipid. This fact would be
expected to reduce the efficiency of the vitamin in its action as a
lipid  antioxidant  and  to  destabilise  rather  than  stabilise
membranes.  
 Mustacich  DJ et.al. [67] reviewed  that  the  most  well-known
function of  vitamin E is that  of  a  chain-breaking antioxidant
that  prevents  the  cyclic  propagation  of  lipid  peroxidation.
Despite its antioxidant function, dietary vitamin E requirements
in  humans  are  limited  only  to  alpha-tocopherol  because  the
other forms of vitamin E are poorly recognized by the hepatic
alpha-tocopherol  transfer  protein  (TTP),  and  they  are  not
converted to alpha-tocopherol by humans. In attempts to gain a
better  understanding  of  vitamin  E's  health  benefits,  the
molecular  regulatory  mechanisms of  vitamin  E have  received
increased attention. 
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AIM OF THE STUDY
The aim of this study is
1. To find whether Vitamin E and Coenzyme Q 10 has lipid lowering
effect in dyslipidaemic patients who receives Atorvastatin therapy.
2. To compare the level of changes in the serum lipid levels between
a group treated with Atorvastatin (Group 1), a group treated with
Vitamin  E  +  Atorvastatin  (Group  2)  and  a  group  treated  with
Coenzyme Q 10 + Atorvastatin (Group 3).
3. To compare the levels of changes in Random blood glucose and
Blood  Pressure  between  the  groups  treated  with  Atorvastatin
(Group 1), a group treated with Vitamin E + Atorvastatin (Group
2) and a group treated with Coenzyme Q 10 + Atorvastatin (Group
3).
.
Department of Pharmacy Practice, K.M. College of Pharmacy, Madurai Page 73
                                                                                                                        Methodology
METHODOLOGY
This  study  was  performed  in  the  cardiology  department  of
Meenakshi Mission Hospital and Research Centre (MMHRC), Madurai,
under  the  co-guidance  of  Dr.  S.  Selvamani,  M.D.,  DNB  (internal
medicine)., DNB(cardiology) [interventional cardiologist].
Design of Study        : Randomized Controlled Study
Sample Size               : 60 patients
Study Duration          : June 2013 – February 2014
No. of Groups           : 3
Drugs Used
Group 1:  Atorvastatin 40 mg/day (Storvas 40 mg tablets)
Group  2:  Vitamin  E  400  mg/day  (Evion  400  soft  gelatin
capsules) + Atorvastatin 40 mg/day 
Group  3:  Coenzyme  Q  10  30  mg/day  (CoQ  30  soft  gelatin
capsules) + Atorvastatin 40 mg/day   
Parameter Measured: Serum Lipid Profile
Inclusion Criteria
     1. Patients who had serum lipid levels
Total Cholesterol > 200 mg/dL
LDL          > 130 mg/dL
HDL             < 35 mg/dL
Triglycerides  > 170 mg/dL
VLDL            > 36 mg/dL
2. The patients who take Atorvastatin 40 mg/day
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3. Patients whose age was in the range 30 to 70 years
4. Both Diabetic and Hypertensive patients were also included
Exclusion Criteria
1. Patients  with  hypersensitivity  to  Atorvastatin,  Vitamin E and
Coenzyme Q 10
2. Smokers
3. Pregnant and lactating women
4. Patients with Arrhythmias and Congestive Heart Failure
5. Patients  taking  any  antioxidant  other  than  Vitamin  E  and
Coenzyme Q 10
Method of work
All the 60 patients enrolled for the study were divided in to three
groups randomly. Group 1, Group 2 and Group 3. Their case history
were collected and documented. 
Then the baseline lipid profile was taken for all the 60 patients
and documented. Then Group 1 patients treated with Atorvastatin 40
mg/ day / oral. Group 2 patients was taken Vitamin E 400 mg / day +
Atorvastatin 40 mg / day orally. Group 3 patients received Coenzyme
Q 10 30 mg/day + Atorvastatin 40 mg / day orally.
All the three groups of patients were monitored for compliance,
and for ADRs. At the end of 4 months the lipid profile of the patients
were taken again as the end point. Then the lipid profiles of Group 1,
Group 2 and Group 3 were compared.
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Statistical Tool
All  the  data  were  recorded  in  the  Master  Chart.  The  Data
Analysis was done using GraphPad InStat DTCG (GPI v 3.0). Mean,
Standard  Deviation,  Student  unpaired  t-test  and  ‘p’  values  were
calculated for  quantitative  variables.  The  ‘p’  values  were  two-tailed
and  obtained  by  using  the  student’s  unpaired  t-test,  with  the
standard deviations of each value to be different. ‘p’ value less than
0.05 was considered to imply a significant relationship.
The  comparative  charts  were  drawn  using  the  mean  of  the
values of different parameters.
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OBSERVATION
Clinical Features
In the study, all three groups had various ranges of difference in
age,  sex,  status  of  disorders,  family  history  of  dyslipidaemia,  and
smoking.  So  there  was  a  requirement  of  distributions  to  ensure
whether  there  is  any  significant  influence  from  any  of  the  foresaid
factors.
All the patients of three groups had a wide range of serum lipid
levels.  So  mean  and  standard  deviation  was  calculated  for  all  the
values.  The  ‘p’  value  of  all  the  parameters  were  measured  by
considering the standard deviation of all the values to be different.
In Group 1 there were 6 diabetic patients, in Group 2 there were
10  diabetic  patients  and  in  Group  3  there  were  also  10  diabetic
patients.  They  were  already  under  anti-diabetic  therapy.  The
reduction in random blood glucose was monitored for these patients
only.
In addition, in the Group 1 there were 7 hypertensive patients,
in Group 2 there were 6 hypertensive patients and in Group 3 there
were  7  hypertensive  patients.  These  patients  were  also  under  anti-
hypertensive therapy. The reduction in blood pressure was monitored
for  these  patients  only.  The  reduction  in  systolic  and  diastolic
pressure were monitored and tabulated separately.
The  percentage change in lipid profile, random blood glucose,
and blood pressure were also calculated. Charts were also drawn to
easily assess the results. Mean value of the parameters were used to
draw the charts.
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Age Distribution
In this study, patients from the age limits of 30 and 70 years
were enrolled. So there may be chances for the age to influence the
results.  So  a  distribution  of  age  between  the  three  groups  were
established. Table 7 and Fig. 2 represent the distribution.
Table 7. Age Distribution
Study Groups
Age (in years)
Total ‘p’ value
≤ 50 > 50
Group 2: Vitamin E 400 mg/day +
Atorvastatin 40 mg/dayNo. of
Patients
Group 1: Atorvastatin 40
mg/ day
No. of
Patients
7 13 20
Group 3: Coenzyme Q 10
30 mg/day +
Atorvastatin 40 mg/day
No. of
Patients
6 14 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig. 2
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Gender Distribution
Group 1 had 14 male and 6 female patients, Group 2 had 15
male  and  5  female  patients.  In  Group  3  there  are  12  male  and  8
female patients.
Table 8. Gender Distribution
Study Groups
Gender
Total ‘p’ value
Male Female
Group 1
No. of
Patients
14 6 20
0.9631Group 2
No. of
Patients
15 5 20
Group 3
No. of
Patients
12 8 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig.3
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Distribution for Diabetes mellitus
Group  1  had  6  diabetic  patients,  Group  2  had  10  diabetic
patients and Group 3 also had 10 diabetic patients. A distribution was
established  to  see  whether  the  blood  glucose  level  influence  the
results.
Table 9. Distribution for Diabetes mellitus
Study Groups
Diabetes Mellitus
Total ‘p’ value
Diabetic Non Diabetic
Group 1
No. of
Patients
6 14 20
0.5661Group 2
No. of
Patients
10 10 20
Group 3
No. of
Patients
10 10 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig. 4
Distribution for Hypertension
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In this study Group 1, Group 2 and Group 3 had 7, 6 and 7
hypertensive patients respectively. 
Table 10. Distribution for Hypertension
Study Groups
Hypertension
Total
‘p’
valueHypertensive
Non
Hypertensive
Group 1
No. of
Patients
7 13 20
0.5732Group 2
No. of
Patients
6 14 20
Group 3
No. of
Patients
7 13 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig. 5
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Distribution for Family History
In Group 1, Group 2 and Group 3, 4, 7 and 6 patients had a
family history of dyslipidaemia respectively. 
Table 11. Distribution for Family History
Study Groups
Family History of
Dyslipidaemia Total ‘p’ value
Yes No
Group 1
No. of
Patients
4 16 20
0.7326Group 2
No. of
Patients
6 14 20
Group 3
No. of
Patients
7 13 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig. 6
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Distribution for Smoking
  In Group  1, eight  patients,  in  Group 2, nine Patients  and in
Group 3, twelve patients were smokers before starting this therapy.
Table 12. Distribution for Smoking
Study Groups
Smoker
Total ‘p’ value
Yes No
Group 1
No. of
Patients
8 12 20
0.8474Group 2
No. of
Patients
9 11 20
Group 3
No. of
Patients
12 8 20
The  ‘p’  value  was  greater  than  0.05.  It  implies  an  insignificant
relationship.
Fig. 7
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Changes in Lipid Profile
Changes in Serum Total Cholesterol Level
Fig.8 and Table 13 imply that the Mean change in serum total
cholesterol level in all three Groups were significant. 
Table 13. Changes in Serum Total Cholesterol Level
Study
Groups
Serum Total Cholesterol (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
244.58 ±
18.57
233.26 ±
16.63
11.32 4.63 0.2427
Group 2
245.44 ±
19.14
225.76 ±
17.87
19.68 8.02 0.1456
Group 3
246.32 ±
22.82
218.64 ±
14.37
27.68 11.24 0.1040
Fig. 8
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Changes in Serum LDL Level
Fig.9 and Table 14 imply that the Mean change in serum Low
Density Lipid level in all three Groups were significant. 
Table 14. Changes in Serum LDL Level
Study
Groups
Serum LDL (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
189.94 ±
19.93
183.44 ±
20.19
6.50 3.42 0.3670
Group 2
186.54 ±
17.28
163.36 ±
14.57
23.18 12.43 0.0910
Group 3
191.72 ±
20.36
152.61 ±
18.65
39.11 20.40 0.0520
Fig.9
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Changes in Serum Triglyceride Level
Fig.10  and  Table  15  imply  that  the  Mean  change  in  serum
Triglyceride level in all three Groups were significant. 
Table 15. Changes In Serum Triglyceride Level
Study
Groups
Serum Triglycerides (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
244.13 ±
43.36
226.54 ±
31.60
17.59 7.21 0.1821
Group 2
241.84 ±
38.69
215.36 ±
28.12
26.48 10.95 0.1214
Group 3
246.37 ±
42.62
208.12 ±
33.17
38.25 15.53 0.0775
Fig.10
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Changes in Serum HDL Level
Fig.11 and Table 16 imply that the Mean change in serum HDL 
level in Group 1, Group 2 and Group 3 were significant.
Table 16. Changes in Serum HDL Level
Study
Groups
Serum HDL (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
30.07 ±
7.01
36.13 ±
6.13
6.06 20.15 0.0004
Group 2
32.24 ±
6.36
40.78 ±
4.88
8.54 26.49 0.0002
Group 3
31.39 ±
5.84
40.89 ±
5.22
9.50 30.26 0.0001
Fig. 11
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Changes in Serum VLDL Level
VLDL levels decreased  in all the groups. Fig.12 and Table  17
imply that the Mean change in serum VLDL levels in Group 1 was
insignificant. Whereas Group 2 and Group 3 were significant.
Table 17. Changes in Serum VLDL Level
Study
Groups
Serum VLDL (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
74.88 ±
34.08
69.31 ±
32.28
5.57 7.44 0.6391
Group 2
78.45 ±
31.62
59.22 ±
30.18
19.23 24.51 0.1826
Group 3
73.54 ±
35.41
51.14 ±
28.80
22.40 30.46 0.1522
Fig.12
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Changes in Random Blood Glucose Level
Fig.13  and  Table  18  imply  that  the  Mean  change  in  random
blood glucose level in Group 1 was insignificant and that of Group 2
was significant.
Table 18. Changes in Random Blood Glucose Level
Study
Groups
Random Blood Glucose (mg/dL) [mean]
‘p’ value
Baseline Endpoint Difference %
Group 1
187.5 ±
33.24
175.75 ±
33.32
11.75 6.27 0.4926
Group 2
183.78 ±
30.14
148.61 ±
32.20
35.17 19.14 0.0378
Group 3
181.0 ±
35.74
147.40 ±
34.18
33.60 18.56 0.0464
Fig. 13
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Changes in Blood Pressure Readings
Fig.14  and  Table  19  show  that  the  Mean  change  in  Systolic
Blood  Pressure  Reading  in  Group  1,  Group  2  and  Group  3  were
significant.
Table 19. Changes in Blood Pressure Readings (Systolic)
Study
Groups
Blood Pressure (mm Hg) [mean]
‘p’ valueBaseline Endpoint Difference %
Systolic Systolic
Group 1
152.14 ±
8.59
147.6 ±
8.33
4.54 2.98 0.3792
Group 2
156.64 ±
8.61
133.3 ±
7.89
23.34 14.90 0.0485
Group 3
154.38 ±
6.78
140.5 ±
6.74
13.88 8.99 0.1425
Fig. 14
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Fig.15 and Table 20 show that the Mean change in Diastolic Blood 
Pressure Reading in Group 1was insignificant and that of Group 2 
was not quite significant.
Table 20. Changes in Blood Pressure Readings (Diastolic)
Study
Groups
Blood Pressure (mm Hg) [mean]
‘p’ valueBaseline Endpoint Difference %
Diastolic Diastolic
Group 1 100 ± 8.16
98.57 ±
7.46
1.43 1.43 0.739
Group 2
104.3 ±
6.18
97.13 ±
6.92
7.17 6.87 0.062
Group 3
102.5 ±
7.07
96 ± 6.07 6.50 6.34 0.073
Fig. 15
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RESULTS AND DISCUSSION
In this study Group 3 shows excellent reduction in serum Total
Cholesterol  than  Group  2  and  Group  1.  Group  2  shows  better
reduction in serum Total Cholesterol than Group 1 (Table 13).
The reduction in serum LDL level in Group 3 was higher than
that of Group 2 and Group 2 was higher than that of Group 1 the
reduction was found to be statistically significant (Table 14).
The reduction in serum triglyceride level in Group 3 was higher
than that of Group 2 and Group 2 was higher than that of Group 1
the reduction was found to be statistically significant (Table 15).
The increase in serum HDL level in Group 3 was higher than
that of Group 2 and Group 2 was higher than that of Group 1 the
reduction was found to be statistically significant (Table 16).
The reduction in serum VLDL level in Group 3 was higher than
that of Group 2 and Group 2 was higher than that of Group 1 the
reduction was found to be statistically significant (Table17).
The reduction in random blood glucose level  in Group 3 was
higher than that of Group 2 and Group 2 was higher than that of
Group  1  the  reduction  was  found  to  be  statistically  significant
(Table18).
7. a. The reduction in systolic blood pressure in Group 3 was higher
than that of Group 2 and Group 2 was higher than that of Group 1
the reduction was found to be statistically significant (Table 19).
    b. The reduction in diastolic blood pressure in Group 3 was higher
than that of Group 2 and Group 2 was higher than that of Group 1
the reduction was found to be statistically significant (Table 20).
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In this study 30 mg/day of Coenzyme Q 10 was given to the
patients of  Group 3. The observation shows that the baseline lipid
profiles have improved at the end of the study.                         
Group 1 showed 4.63 % reduction in serum total  cholesterol
(Table 13). This reduction may be due to the Atorvastatin 40 mg taken
by the patients. In Group 2, there was an 8.02 % reduction of the
same. This additional reduction may be due to the adjuvant therapy
with Vitamin E. But In Group 3, there was an 11.24 % reduction of
TCL.  This  is  due  to  the  adjuvant  therapy  with  Coenzyme  Q  10.
Statistically the difference showed significance (Table 13). By this it
can  be  said  that  reduction  in  serum  total  cholesterol  is  more
significant  only  when  Atorvastatin  is  given  in  combination  with
Coenzyme Q 10.                         
The reduction of  serum LDL level  (Table  14) in Group 3 was
again much higher than that in Group 2 and Group 1. In Group 1 the
reduction was only 3.42 %, in Group 2 the reduction was 12.43 % and
in  Group  3,  the  reduction  20.40  %.  Statistically  the  reduction  in
serum LDL in Group 3 is significant (Table 14) when compared with
that  of  Group  2  and  Group  1.This  implies  that  LDL  reduction  is
powerful when Atorvastatin and Coenzyme Q 10 combination is given.
In Group 1 the reduction in the serum triglyceride level (Table
15) was 7.21 %, in Group 2 it was 10.95 %. But in Group 3 reduction
was 15.53 %. The difference in reduction was statistically significant
(Table  15).  This again states that Atorvastatin and Coenzyme Q 10
combination is preferable.
The increase in the serum HDL level (Table 16) in Group 1 was
20.15 %.  In group 2 26.49 % but in Group 3 serum HDL was 30.26
%,  and it  was  statistically  significant  (Table  16).  This  implies  that
Coenzyme Q 10 can have a significant effect in increasing serum HDL
levels  when  it  is  given  with  a  HMG CoA reductase  inhibitor.  This
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shows that there is a special mechanism by which Coenzyme Q 10
increases serum HDL level.
The reduction of serum VLDL level (Table 17) in Group 3 was
higher than that of other two Groups. In Group 1 the reduction was
7.44  %,  in  Group  2  the  reduction  was  24.51  %.  But  in  group  3
reduction was 30.46 %. This reduction was found to be statistically
significant (Table 17). This again proves a combination of Statin and
Coenzyme Q 10 highly effective in lipid lowering effect.                         
Apart from lipid lowering the hypoglycaemic effect of Coenzyme
Q  10  was  also  monitored.  It  revealed  that  Coenzyme  Q  10  has
considerable  anti-diabetic  effect,  and  the  ‘p’  value  expressed
significance (Table 18). Group 3 also showed a considerable reduction
in systolic B.P. and it was statistically significant (Table 19). But the
diastolic blood pressure in Group 2 shows very significant reduction
(Table 20).
On the whole the comparison of reduction in lipid parameters
shows that Atorvastatin + Coenzyme Q 10 combination has a powerful
lipid  lowering  effect,  when  compared  to  Atorvastatin  +  Vitamin  E
combination and Atorvastatin alone.                       
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CONCLUSION
As  per  the  observations  and  results  we  can  conclude  that
Coenzyme Q 10 possess lipid lowering effect in dyslipidaemic patients.
Coenzyme Q 10 reduces serum total cholesterol and serum LDL,
and  increases  serum  HDL  when  given  in  combination  with
Atorvastatin. It also shows marked influence in reducing the random
blood glucose and blood pressure.
Currently Coenzyme Q 10 is not prescribed by physicians for
lowering serum lipid levels, because of inadequate studies on the lipid
lowering effect  of  Coenzyme Q 10,  and the cost  of  the  medication.
Each 30 mg capsule of Coenzyme Q 10 is Rs.19.
But,  considering  its  therapeutic  efficacy,  safety,  and  other
beneficial  effects,  Coenzyme  Q  10  can  be  recommended  for
prescription to dyslipidaemic patients.
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Appendix
Patient Profile Format
Name:                                   Sex:                         D.O.B. & Age:
Weight:                                 Height:                     Nationality:
Residential Address:
Contact No.:
Hospital No.:
Medical History:
Medication History:
Sensitivity to Drugs:
Lipid profile:
Serum
Lipid
Level
(mg/dL)
Total
Cholesterol
LDL Triglycerides HDL VLDL
Base-line
End-point
Random Blood Glucose:
Base-line:
End-point:
Blood Pressure:
Blood Pressure Systolic Diastolic
Base-line
End-point
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